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The 12th meeting of the Scientific Group on Methodologies for the Safety Evaluation of
Chemicals (SGOMSEC) considered the topic of methodologies for determining human and
ecosystem susceptibility to environmental hazards. The report prepared at the meeting describes
measurement of susceptibility through the use of biological markers of exposure, biological
markers of effect, and biomarkers directly indicative of susceptibility of humans or of
ecosystems. The utility and validity of these biological markers for the study of susceptibility are
evaluated, as are opportunities for developing newer approaches for the study of humans or of
ecosystems. For the first time a SGOMSEC workshop also formally considered the issue
of ethics in relation to methodology, an issue of particular concern for studies of susceptibility.
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Enxvionmental Hazards factors, diet, socioeconomic status, age,
and gender. The intrinsic susceptibility of
Individuals vary greatly in their likelihood an individual is altered by inherited muta-
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This joint report was developed at the Workshop on Susceptibility to Environmental Hazards convened by the
Scientific Group on Methodologies forthe Safety Evaluation of Chemicals (SGOMSEC) held 17-22 March 1996
in Espoo, Finland. Manuscript received at EHP5 November 1996; accepted 18 November 1996.
Address correspondence to Dr. B.D. Goldstein, Environmental and Occupational Health Sciences Institute,
681 Frelinghuysen Road, PO Box 1 179, Piscataway, New Jersey 08855-1179. Telephone: (908) 445-0205.
Fax: (908) 445-0131. E-mail: bgold@eohsi.rutgers.edu
Abbreviations used: AAS, atomic absorption spectrophotometry; AHH, aryl hydrocarbon hydroxylase; -ALA,
-aminolevulinic acid; 1-HP, 1-hydroxypyrene; CA, chromosome aberration; CDGE, constant gradient gel elec-
trophoresis; CYP, cytochrome P450; DGGE, denaturing gradient gel electrophoresis; ELISA, enzyme-linked
immunosorbent assay; EDTA, ethylenediamine tetraacetic acid; EROD, ethoxyresorufin 0-deethylase; FISH, flu-
orescent in situ hybridization; GPA, glycophorin A; GSTM1, glutathione Stransferase Ml; GSTT1, glutathione
Stransferase Ti; HPLC, high performance liquid chromatography; HPRT, hypoxanthine phosphoribosyl-trans-
ferase; HUGO, Human Genome Project; ICSU, Intemational Council of Scientific Unions; MN, micronuclei; ILO,
International Labor Organization; IPCS, International Programme on Chemical Safety; MFO, mixed-function oxi-
dase; MXR, multixenobiotic resistance mechanism; OP, organophosphate; PDGF, platelet-derived growth factor;
PCB, polychlorinated biphenyl; PCDF, polychlorinated dibenzofuran; PCDD, polychlorinated dibenzo-p-dioxin;
PAH, polycyclic aromatic hydrocarbon; PCR, polymerase chain reaction; PSA, prostate-specific antigen; QC, quak
ity control; OA, quality assurance; RFLP, restriction fragment length polymorphism; RBP, retinal binding protein;
RT, reverse transcription; SGOMSEC, Scientific Group on Methodologies for the Safety Evaluation of Chemicals;
SCOPE, Scientific Committee on Problems of the Environment; SSCP, single-strand conformation polymor-
phism; SCEs, sister chromatid exchange; TCB, tetrachlorobiphenyl; TCDD, tetrachlorodibenzopdioxin; TEF, toxic
equivalentfactor;WHO, World Health Organization; XRF, X-rayfluorescence; ZPP, zinc protoporphyrin.
metabolic activation or detoxification of
environmental toxins, and genes control-
ling the repair ofDNA or cellular damage.
Epigenetic changes in expression ofthese
genes can also affect host susceptibility.
These alterations may be due to inherited
differences in genes that control the expres-
sion ofother genes, to past environmental
exposures, to the physiological state ofan
individual, to age-related differences, or to
developmentally controlled processes. The
interaction between genes and the environ-
ment, the cross talk between genes, and the
interplay ofenvironmental factors, which
include diet and lifestyle, illustrate the com-
plexity in understanding the susceptibility
to environmental hazards.
Recent advances in the understanding
ofmolecular biology, the human genome,
toxicology, and disease mechanisms and
ecosystem functions have led to significant
advances in the study ofsusceptibility fac-
tors for environmental hazards. These
methods can be used to identify environ-
mental causes ofhuman diseases and harm
to ecosystems; to identify susceptible sub-
populations; and to understand interindi-
vidual and interethnic differences in
response to environmental hazards, which,
we hope, will lead to disease prevention, an
important translation ofmolecular medi-
cine. The complex interplay between genes
and environment represents a tremendous
challenge to scientists but also an impor-
tant opportunity to reduce the burden of
disease and dysfunctions to humans and
the ecosystem.
The number ofbiomarkers available to
study responses ofbiological systems to
environmental factors is growing rapidly.
The term "biomarker" is a general term for
specific measurements ofan interaction ofa
biological system and an environmental
agent (1,2). Biomarkers ofexposure mea-
sure an exogenous substance or its metabo-
lite and its interaction with a biological
molecule. Because a number of factors
determine whether a chemical exposure
reaches its biological target for a toxic
response, the most accurate measurement
of"dose" is the biologicallyeffective dose at
the target tissue, which can be more reliably
measured by biomarkers ofexposure than
estimated by measurements ofadministered
or ambient chemical exposure.
Biomarkers of effect are measurable
biochemical, physiological, behavior, or
other alterations within an organism (1).
Biomarkers ofeffect areprimarilyconcerned
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Figure 1. The role of susceptibility in the continuum between biological markers of exposure and of effect.
with adverse effects, although the level of
evidence varies for the relationship between
a given measured effect and specific, patho-
logical responses, which occur often after a
long period and after chronic exposures.
There is an overlap between biomarkers of
exposure and biomarkers ofeffect, because
the same biomarker can be used for both
measurements. Some ofthe same biomark-
ers are also used to measure interindividual
differences in response and thus further
serve as biomarkers ofsusceptibility.
There is a continuum between biologi-
cal markers ofexposure and those ofeffect
(Figure 1). Exploring the relationship
between biological markers on this contin-
uum can be a useful means for detecting
susceptibility. Biological markers ofsuscep-
tibility can be defined as indicators of the
mechanistic processes that cause variability
among the compartments in the continuum
between exposure and effect.
As a simplification, there are five differ-
ent mechanistic avenues through which fac-
tors affecting susceptibility can influence the
interaction between biological systems and
environmental exposures. These avenues are
body uptake, metabolism, target cell uptake,
subcellular or molecular interaction, and the
baseline status ofthe individual or ecosys-
tem. The mechanistic avenues are bounded
by compartments in which exposure or
effect can be quantitated. These compart-
ments are external exposure level, internal
exposure level, extracellular level of toxic
agent or metabolite, cellular level of toxic
agent or metabolite, target cell toxicity, and
adverse effect to the individual or ecosystem.
In each case one or more of the mecha-
nisms responsible for susceptibility produce
a variation in the relation between compart-
ments that is potentially detectable through
useofbiomarkers.
In the simplest formulation, susceptibil-
ity can be defined as a variation in the
quantity ofexposure/effect in a compart-
ment among individuals or populations
who have similar levels ofexposure/effect in
the preceding compartment. Ofnecessity,
this can only be accounted for by mecha-
nisms operative in the avenue between
these two compartments. Examples of
compartments and mechanistic avenues are
the following:
* For a given level ofexternal exposure,
there is an interindividual variation in
the uptake into the body (e.g.,
increased Fe uptake in hemochromato-
sis; variations in uptake ofair pollutants
related to respiratory rate).
* For a given level ofa toxic agent, there
is interindividual variation in the
uptake into the target cell (e.g., increase
in radioactive iodine uptake into the
thyroid in iodine-deficient individuals;
tumor resistance to chemotherapeutic
agents).
* For a given level of uptake into the
body, there is interindividual variation
in the level ofa metabolically produced
active toxic agent (e.g., differing activities
ofmetabolic enzymes).
* For a given level ofuptake into the tar-
get cell there is a variation in the extent
of effect (e.g., glucose 6-phosphate
dehydrogenase deficiency or methemo-
globin reductase deficiency rendering
the red cell susceptible to oxidant stress;
differences in DNA repair).
* For a given level ofeffect in the target
cell, there is a variation in the impact
on the individual (organ functional
reserve capacity variations due to age;
disease factors).
* For a given level ofeffect in an organ-
ism, there is a variation in the impact
on communities and ecosystems (e.g.,
shifts in biomass, species diversity,
energy cycling due to heavy metals or
organochlorines).
Each mechanistic avenue can have mul-
tiple inputs in different directions, which
influence the extent to which a quantity in
one compartment affects the quantity in
the next compartment. For example, even
when the relation between the absorbed
dose ofa xenobiotic and the level ofa toxic
metabolite is the result ofa single enzyme,
the activity ofthis enzyme in any individ-
ual may be a function of a genetic poly-
morphism as well as the presence ofother
pollutants or ofdietary factors that affect
enzyme activity. The potential order ofthe
compartments may differ depending upon
the mechanistic pathways; e.g., metabolism
may occur in a nontarget cell and precede
uptake ofthe toxic metabolite into the tar-
get cell (reversal of the second and third
sections in the above example). The rela-
tionship between compartments can be
modeled mathematically so as to explore
the extent ofvariability in the relationship
between two compartments among a speci-
fied population group, i.e., the distribution
of susceptibility due to this particular
mechanistic avenue.
In essence, the true distribution of
susceptibility in a population is the relation
between the first compartment and the last
one-between external exposure and
disease outcome, with the intervening
mechanistic avenues contributing to this
distribution. For a given individual it is
possible that a mechanism that increases
susceptibility to a disease outcome in one
avenue may be counterbalanced by a mech-
anism that decreases susceptibility in
another avenue. It is thus important to rec-
ognize that analysis ofonly one mechanistic
avenue in the pathway between exposure
and disease does not necessarily provide
definitive information on the susceptibility
ofanysingle individual in the population.
Biomarkers can be divided into those
that measure compartments, e.g., blood
levels, DNA adducts, or tissue damage; and
those that measure mechanisms, e.g.,
enzyme activity levels or gene polymor-
phisms. Each has its advantages and its
limitations. Measurement ofthe compart-
ment tells little about the reasons for the
level; measurement of the mechanism is
not always a definitive indicator ofwhat
will be happening in the next compart-
ment. For individuals or populations at
risk, it is preferable to have measurements
both from mechanistic avenues and from
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related compartments to more effectively
target prevention strategies.
GeneticSusceptibility
Individuals may vary in terms of their
responses to environmental hazards due to
differences in their genetic constitution.
The human genome encodes for 50,000 to
100,000 genes, some ofwhich are key regu-
lators of biological processes. Mutations
(heritable alterations in the primary coding
sequences of genes or their controlling
elements) in specific genes ("disease genes")
greatly predispose an individual to a dis-
ease. For example, mutations that inacti-
vate the retinoblastoma gene, a central
regulator ofcell growth and division, can
result in a 105-fold increased probability of
a rare eye cancer in children (retinoblas-
toma). Due to recent advances in gene
mapping and isolation, a number ofmajor
disease genes have been discovered, includ-
ing genes involved in cystic fibrosis;
Huntington's disease; Alzheimer's disease;
and breast, colon, lung, and many other
cancers. Mutations in disease genes lead to
a very high probability ofdisease develop-
ment, often approaching a 100% incidence
ofdisease in carriers ofthe mutations.
Mutations in disease genes are usually
rare; depending on the gene, 1 in 200 to 1
in a million people are affected. However,
multiple genes may regulate a specific dis-
ease, therefore, the percentage of disease
cases for which there is a genetic compo-
nent may be high. For example, in certain
cancers (e.g., colon, breast, and prostate) it
is estimated that up to 10% ofthe cancers
are due to a genetic predisposition. These
very strong susceptibility genes may not be
influenced by environmental factors, but
there is evidence for environmental influ-
ences in some diseases even with a strong
genetic predisposition.
Many of the genes in the genome of
humans and other species influence the
impact of environmental agents on the
organism. Genetic controls on the uptake,
activation, detoxification, or repair ofenvi-
ronmental insults are known. The exact
number of genes involved in the organ-
ism's response to environmental hazards is
unknown but could be very large. For
example, the estimates ofthe number ofthe
individual P450 genes in any mammalian
species range from 60 to 200 (3).
All genes commonly have variations in
their sequences that may or may not have
functional consequences. Changes in
DNA sequence that occur frequently (in
> 1% ofthe population) are called genetic
polymorphisms. Polymorphisms often
affect the function ofa gene but some may
change the level ofexpression ofa gene or
change the activity of the gene product,
for example, an enzyme. Genetic polymor-
phisms that are functionally significant are
quite important when the gene controls
the response of an organism to environ-
mental hazards. For example, polymor-
phisms in the genes that metabolize
carcinogens can affect the response ofindi-
viduals to that carcinogen. Given that a
large number of genes are involved in
responses to environmental hazards and
that a large number ofpolymorphisms exist
in these genes, genetic differences are
important susceptibility factors in environ-
mental responses. Many ofthese commonly
occur in human populations.
Recent advances in the identification
and cloning ofspecific genes and methods
for the detection of mutations and poly-
morphisms in these genes have led to sig-
nificant advances in our understanding of
genetic susceptibility to environmental haz-
ards. There is an important difference
between individuals with genetic alter-
ations that lead to disease susceptibility and
individuals with genetic susceptibility to
environmental factors. Individuals who
inherit a mutation in a disease susceptibil-
ity gene have a high risk ofdeveloping that
disease regardless of environmental expo-
sures, although environmental factors may
increase the incidence or rate of disease
development. Individuals who have a
mutation or polymorphism in genes
involved in response to environmental haz-
ards will only have an increased risk ofdis-
ease development when they are exposed to
specific environmental hazards. Therefore,
risk to these individuals is influenced
strongly by gene-environment interaction.
Also, because multiple genes are involved
in response to the same environmental haz-
ards, two individuals with the same genetic
susceptibility and environmental exposure
may have different risks because of the
interplay between genes involved in
response to xenobiotics. For example, two
individuals may both have a polymorphism
in a gene that increases the rate ofcarcino-
gen activation but different polymorphisms
in a gene that inactivates the same carcino-
gen. Because many environmental response
genes remain to be identified and charac-
terized and because many mixtures ofenvi-
ronmental exposures are present in the
environment, it is difficult to determine an
individual's risk. Great advances have been
made in the identification ofsusceptibility
factors for subpopulations exposed to
environmental hazards.
SusceptiblePopulationsversus
SusceptibleInaividuals
Environmental and occupational medicine,
like medicine in general, is traditionally
concerned with individuals and their
health. It may also seek to identify individ-
uals who are liable to develop a specific dis-
ease (predictive medicine). This approach
implies the possibility ofdividing the peo-
ple into two groups: those who are disease
prone, and the healthy remainder. This is,
ofcourse, a considerable oversimplification,
because susceptibility is rarely confined to a
distinct high-risk minority and because our
ability to predict the disease outcome for
these individuals is thereforeweak.
Epidemiology, as a discipline ofpublic
health, includes the study ofthe distribu-
tion ofdiseases and risk factors in popula-
tions. Epidemiologic research focuses on
populations in order to elucidate a broad
range ofrisk factors for disease. A distinc-
tion exists between the populations that
epidemiologists study and the individuals
comprising those populations. Within a
low risk population, there are individuals
who develop disease, and within high-risk
populations there are disease-free individu-
als. An individual's risk will be determined
by a complex interplay ofmultiple genes,
multiple exposures, diet, age, and chance.
The application ofbiomarkers ofexposure,
effect, and susceptibility to the assessment
ofan individual's risk from environmental
hazards is not conceptually different from
the application of common clinical mea-
sures in medical practice. For example,
blood pressure, blood lipids, relative
weight, and smoking habits are applied to
the assessment of an individual's risk for
coronary heart disease in clinical medicine.
Combining biomarkers with epidemiologi-
cal studydesign has led to the development
of molecular epidemiology, an approach
that generates a great deal ofinterest and
expectation. The use of biomarkers in
human studies raises challenging ethical
questions that must be addressed in
advance ofapplying new technologies in
this area.
Susceptible Populations
andEcsysems
Ecologists are concerned with understand-
ing differences in susceptibility among
individuals within communities of thou-
sands ofspecies. One important method-
ological approach is the development of
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biomarkers ofexposure and effect that are
applicable across a broad range ofspecies
that range from invertebrates to birds and
mammals. However, ecologists also are
concerned with understanding and predict-
ing-through the use ofbiological indica-
tors-differences in susceptibility of
communities and ecosystems. Here, vul-
nerability refers to changes in the structure
and function ofecosystems. The challenge
for ecologists is to develop a broad range of
methodologies from molecular through
ecosystem measures that can be used to
assess susceptibility.
In many cases, cellular and molecular
biomarkers that can be used to assess the
susceptibility ofa range ofindicator species
will be most useful for communities and
ecosystems as well. Such biomarkers could
be used to assess both the health of the
ecosystem and the potential ofthe ecosys-
tem to support human populations and
provide ecological services.
Ethics
The study of susceptibility in human
populations and in ecosystems poses a
number ofethical challenges. Regarding
humans, both the manner in which infor-
mation is obtained and the uses to which
it could be put raise urgent concerns.
Regarding ecosystems, the ethical duty to
work towards protecting our shared environ-
ment and its life support systems requires
ongoing attention and the development of
clear guidelines.
Specifically relevant to susceptibility
studies in humans is the sensitivity of the
information and the likelihood oflabeling
certain individuals or subgroups in ways
that could cause unanticipated harm.
Scientists and public health professionals
investigating susceptibility or implementing
related preventive screening programs must
be aware ofthe potential for harmful social
and psychological side effects arising from
susceptibility studies. For example, denial
ofemployment, denial ofinsurance, fear for
the premature onset of illness or death,
social marginalization, reconsideration of
family planning and ofboth medium and
longer term life goals, and the need for psy-
chological counseling are possible untoward
effects that may arise from the identification
ofsusceptibility in individuals.
Scientists also must remain sensitive to
cross-cultural differences in perception of
personal risks associated with susceptibility
studies and must strive for equity in their
research and in its potential consequences.
For example, there may be greater need to
focus resources on populations subjected to
more severe pollution than on those popula-
tions experiencinglowerlevels ofexposure.
Scientists must understand ethical
issues to be able to address the challenges
presented by susceptibility studies and to
learn how to resolve them. Preparation
would include defining the key ethical
issues, identifying the principles behind
them, and then attempting to resolve the
ethical dilemmas that emerge. This objec-
tive requires a certain amount of formal
training in ethics as well as ongoing dia-
logue involving a broad range ofstakehold-
ers who try to anticipate ethical dilemmas.
Stakeholders include, among others, other
professionals as well as patient advocates.
Markers of susceptibility are of a
particularly sensitive nature. Therefore,
serious attention must be paid to quality
assurance so that data integrity can be even
more highly assured than in most other
types of studies. In addition, existing
guidelines that protect confidentiality and
ensure the participants' "right to know"
must be revisited and made more specific
in light ofthe potential consequences of
susceptibility studies.
Where legal protections are not clearly
in place to ensure confidentiality ofper-
sonal information gathered in the conduct
ofresearch into susceptibility, and to pro-
tect the various stakeholders against retro-
active actions, the risks associated with
such studies must be made clear to any
research participants in advance of their
commitment to participate. Such risks
include birth with inherited negative traits,
and illness induced or associated with envi-
ronmental/occupational exposures only
subsequently recognized as having been
associated with susceptibility traits.
Finally, susceptible ecosystems exist,
the destruction ofwhich can have both
direct and indirect negative consequences
for human health and well-being. For
example, the susceptibility ofthe earth's
atmosphere has consequences for global
warming associated with, among other
things, increasing skin cancer rates, coastal
flooding disasters, and crop failures.
Scientists engaged in such work must bring
to the attention of human populations
their stewardship duty and responsibility to
protect the ecosphere.
Condusions andRecommendations
The following condusions and recommen-
dations have been formulated in recogni-
tion ofhuman and ecosystem vulnerability
to environmental hazards:
a) Determination ofsusceptibility to
chemicals in theworkplace and general envi-
ronment is becoming increasingly feasible
through rapid advances in biological sci-
ences, particularlymolecularbiology. Parallel
advances have occurred in epidemiology,
ecology, toxicology, and related sciences
which have greatly facilitated understanding
and measurement ofsusceptibility.
b) Increased understanding of the
pathways leading to susceptibility of
individuals, ofpopulations, and ofecosys-
tems to chemical and physical agents is of
value in protecting human health and
the environment.
c) Identification ofbiological markers of
exposure and ofeffect is a useful avenue for
determining susceptibility. Markers ofsus-
ceptibility in essence operate in the pathway
between the various compartments ofexpo-
sure and effect, reflecting mechanisms
responsible for variations in response to the
levels in the previous compartment.
d) There is an important distinction
between studies of the susceptibility of
populations at risk and studies of the sus-
ceptibility of individuals. It is important
not to misinterpret from population
studies the risk to an individual.
e) The ethical, legal, and social dimen-
sions should be recognized in studies of
individuals, populations, communities, and
ecosystems at risk. Ethical dilemmas must
be considered in advance ofresearch activi-
ties or ofany use ofsusceptibility markers
in evaluating populations at risk. In some
cases public debate and legislation will be
required to clarify social norms and to pro-
vide legal protection for the participant.
Ethical issues should be incorporated in the
development ofmethodologies to studyand
evaluate communities and ecosystems and
should be reflected in research proposals.
f) Studies ofbiomarkers ofsusceptibil-
ity should not be undertaken in circum-
stances in which confidentiality and
privacysafeguards cannot be assured.
g) Training programs for professionals
engaging in susceptibility studies of bio-
markers need to integrate formal ethics
education. Continuing education should
include an ongoing discourse through
ethics workshops, symposia, and discussion
in thejournals ofthe respective professions.
h) Numerous other methodological
issues must be taken into account before
accepting a marker ofsusceptibility as being
potentially useful in protecting public
health and the environment. These issues
include technical feasibility, cost, quality
assurance and control, and cultural and
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logistic issues related to sample availability,
collection, and storage.
i) The determination and use ofsuscep-
tibility markers pose both technical and
ethical issues in developing countries. These
need to be taken into account when design-
ing studies or applying the use ofsuscepti-
bility markers validated in industrialized
countries.
j) Additional research is needed to
focus biological advances on increasing
understanding offactors affecting the sus-
ceptibility ofhuman and nonhuman com-
ponents of ecosystems, and to determine
how best to apply this understanding to
protect public health and the environment.
Good science should be tied to good ethics
and vice versa.
Biological Markers
of Exposure
Definition ofExposureMarkers
In the narrowest sense, biomarkers ofexpo-
sure refer to measurement ofthe specific
chemical of interest or its specific metabo-
lite in a body compartment or fluid. In the
broadest sense, it can refer to anybiomarker
used to estimate current or past exposure
for either medical, epidemiologic, or risk
assessment purposes (4). This can even
include the clinical detection ofevidence of
exposure, although this domain is usually
excluded from discussion ofbiomarkers.
Many of the biomarkers of effect are
used also to assess exposure, and some of
these will be discussed in this section. Not
all biomarkers can be used in all settings,
particularly in developing nations (5).
Objectives forUsingBiomarkers
ofExposure
Exposure can beviewed as both apopulation
and an individual phenomenon. Exposure
markers can function in several ways.
a) They may lead to early detection of
exposure at a point where significant health
effects have not occurred. This must focus
attention on external means of reducing
exposure, i.e., on primary prevention.
b) They may provide validation of expo-
sure for use in epidemiologic studies.
c) They may facilitate comparison ofexpo-
sure levels in different compartments
(external, blood, cellular) to identify
susceptibility differences.
Criteria for Sereening, Using
Biomarkers. The application of any
biomarker approach must be conducted
within the context ofaviable screening and
prevention program. The World Health
Organization (WHO) has established a set
of criteria to be met before instituting a
screening program. These will be discussed
in relation to exposure markers.
CRITERION 1. The screening must
be conducted for a condition of public
health significance. Overall the exposure,
health status, or susceptibility ofpopula-
tions or subpopulations is clearly ofpublic
health significance. Thus, criterion 1 is
usually met (but see the section on ethical
considerations).
CRITERION 2. The natural history of
the exposure marker must be well under-
stood, and there must be a distinguishable
subclinical phase. There is tremendous
variability in our knowledge regarding the
natural history ofvarious exposure markers
and their relation to subsequent effects.
CRITERION 3. There must be a scientifi-
cally defensible and socially and personally
acceptable intervention. The usual inter-
vention when an exposure is detected is to
remove the hazard and reduce the exposure;
CRITEIUON 4. The tests used must have
appropriate sensitivity and specificity.
Usually the sensitivity limitation is
imposed by the analytic method available.
Increasingly sophisticated instrumentation
has allowed the measurement ofvarious
analytes at infinitesimally small levels,
although in most cases this sensitivity is not
required. However, it is essential to choose
the appropriate tissue or fluid and method-
ology to assure adequate test sensitivity.
Sensitivity also depends on the proper
timingofanalysiswith respect to exposure.
Measuring the agent ofconcern is usu-
ally highly specific. For example, a blood
lead determination reflects lead exposure.
However, it may not be specific to the
source of lead being investigated since
there are many sources oflead in our envi-
ronment. Specificity in part depends on
the question being asked. For example, one
might be interested in recent exposure or
historic exposure and would design a dif-
ferent testing approach for each. In some
cases, to address specific questions, chemi-
cal speciation ofthe agent or analyte is nec-
essary (e.g., chromium VI vs chromium
III, methyl vs inorganic mercury, organic
vs inorganic arsenic) and speciation, in
turn, may reduce sensitivity.
The metabolites one measures may be
specific or nonspecific. Thus phenol is
commonly used as a marker of benzene
exposure but is not specific (other com-
pounds are metabolized to phenol and
some consumer products, such as cough
medicines, contain phenol). Nonetheless it
may still be useful in quantifying exposure
in individuals known to have relatively
high levels ofexposure to benzene. Other
metabolites are more highly specific (e.g.,
muconic acid for benzene), and others are
very specific (DDE for DDT). Some
metabolites are also active agents.
CRITERION 5. The condition or
exposure being sought must be sufficiently
common that the tests have acceptable pre-
dictive value. Exposure is a phenomenon
common to both a population and an indi-
vidual. On the individual level, the predic-
tive value ofa screening test depends not
onlyon its sensitivity and specificity, but on
the underlying prevalence ofthe exposure.
One can estimate population exposure by
randomly sampling a subgroup ofthe pop-
ulation before extending screening for
exposure biomarkers to alarger population.
CRITERION 6. The testing must be
acceptable to the target population.
Biomarkers of exposure are most often
detected with noninvasive (breath sam-
pling, urine testing) or minimally inva-
sive (milk collection, blood testing)
approaches. At the other end ofthe spec-
trum are fat biopsies which are limited to
clinical diagnostic settings or to specialized
research protocols.
CRITERION 7. The testing program must
be cost effective (see below, on analysis and
quality assurance).
UseofBiomarkers
Applications ofBiomarkers ofExposure.
Monitoring biomarkers of exposure is
usually part ofa preventive activity. It can
contribute to identifying and reducing
exposure or to identifying at-risk or suscep-
tible populations that need to be protected
in special ways. In occupational health, the
major goal ofdetecting biomarkers is the
prevention of health impairment by the
recognition ofexcessive exposure and the
elimination ofhazards (6). Ideally, expo-
sure is controlled and measured at the
source so that no excessive exposure occurs
(7), but often there is supplemental
reliance on biological monitoring as part of
a medical surveillance program, to assure
that the primary preventive strategies have
been effective.
A marker can be applied on an individ-
ual basis to estimate the amount ofpollu-
tant absorbed or retained, usually through
the measurement ofthe agent or its specific
metabolites (8). A marker can reflect
individual differences in the rate ofabsorp-
tion and in toxicokinetics (metabolism,
distribution, and excretion).
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The traditional definition of an expo-
sure biomarker involves measurement ofa
xenobiotic or its metabolite in a body tis-
sue or fluid, whereas markers of effect
include any measurable alteration attribut-
able to a xenobiotic that can be recognized
as a health impairment. Between the two is
a continuum of subtle effects caused by
chemicals that can be measured but which
are not indicative of a disease. Some of
these are early stages in a significant patho-
genic process (e.g., DNA adducts ofalky-
lating agents), others are early, often trivial,
stages in a pathogenic process (zinc proto-
porphyrin [ZPP] elevation in lead expo-
sure), and others may be the early signs of
damage that are reversible and not ofclini-
cal significance (for example, depression of
cholinesterase activity or elevation ofsome
tubular proteins in persons exposed to
heavy metals). In the latter case, it is recog-
nized that kidney function may show no
clinically detectable decrement until about
90% of the nephrons are damaged; hence
substantial changes can occur with no
immediate overt clinical significance except
a reduction in reserve capacity.
Blood lead is a marker ofexposure and
a surrogate marker ofeffect. Elevations of
ZPP or erythrocyte protoporphyrin and
urinary 6-aminolevulinic acid (6-ALA) or
the activity of 6-ALA dehydratase are all
effects caused by lead; the inhibition of
enzymes in the heme synthesis pathway
results in anemia, yet anemia is rarely the
end point of concern in lead poisoning,
especially in adults. Thus, they are useful as
exposure as well as effect markers.
A major criterion for distinguishing
markers ofexposure from markers ofeffect is
the purpose to which they are put. In many
cases enzymatic or cellular damage markers
are used for dose reconstruction or for the
classification of exposure status for epi-
demiologic studies. Van Schooten et al (9),
for example, treat DNA adducts in smok-
ers as a means ofestimating their polycyclic
aromatic hydrocarbons (PAH) exposure.
For the purposes of this discussion we
recognize the following as biomarkers of
exposure: a) measurement ofthe xenobiotic
itself (i.e., lead in blood, DDT in milk);
b) measurement ofspecific metabolites;
c) measurement ofspecific subclinical effects
that are reversible. Many effect markers that
are used to estimate exposure or tissue dose
are described in more detail below.
Choice of Tissue or Fluid and
Analyte. Factors that influence the choice
of tissue or fluid and analyte include the
toxicodynamics of the agent (where it is
distributed, stored, excreted), speciation
(its chemical form), and chronology (acute
vs chronic exposures and temporal aspects
ofits kinetics in the body).
An exposure marker should be able to
distinguish long-term from short-term
exposures (10). Thus blood lead may
reflect recent exposure, while bone lead
reflects cumulative exposure.
An example of the importance of
appropriate quality control (QC) is
reflected in the experience with routine
blood lead determinations by clinical labo-
ratories. As recently as the early 1990s,
when laboratory proficiency testing pro-
grams were concerned with accuracy in the
presumed toxic range of40 pg/dl, it was
found that most laboratories were unable
to provide reliable results below 15 pg/dI,
even though the Centers for Disease
Control had designated 10 pg/dl as a "level
of concern." Two years later, when profi-
ciency testing began to include unknowns
in the 10 pg/dl range, most laboratories
rapidly improved to the point where they
provided acceptable results. It is essential
that a quality assurance (QA) program be
designed for the range ofvalues that will be
encountered in a population.
DNA and Protein Adducts. Many
compounds form covalent adducts with
nucleic acids and other macromolecules
including hemoglobin and other proteins.
In the case ofDNA adducts, the changes in
the DNA molecule may relate directly to
mutational or repair events and the possi-
bility ofsubsequently developing cancer.
Elevated levels ofDNA adducts are seen in
a number ofpopulations with known ele-
vated cancer risks, including smokers and
coke-oven workers.
DNA adducts can be measured by the
32P-postlabeling technique or by immuno-
assays. For certain adducts, mass spectrom-
etry, fluorescence spectrometry, and liquid
chromatography/electrochemical detection
have been used. For quantitative analysis a
standard compound is necessary for the
calculation of recovery as discussed by
Hemminki (11). In the case of complex
mixtures, identification of individual
adducts may not be possible. In such cases
recoveries cannot be calculated and quan-
tification is not possible. Data on half-lives
of adducts in humans are very limited.
Biomonitoring ofprotein adducts applies
to either hemoglobin or albumin. Adducts
can be released hydrolytically from the pro-
tein and assayed by gas or liquid chro-
matography, or by mass spectrometry.
N-terminal valine ofhemoglobin can be
specifically released in the Edman degrada-
tion process and assayed by mass spectrome-
try. Adducts are generally not thought to
alter the half-lives ofthe proteins.
DNA-protein cross-links are another
end point that has been used to estimate
exposure to mutagens such as hexavalent
chromium (12). A standardized DNA
extraction procedure is used that fails to
extract cross-linked DNA that can be
quantified as apercentage ofthe total DNA.
Assessing Population Exposures.
Examples ofexposure markers used to docu-
ment the effectiveness of regulatory inter-
ventions are the dramatic decline in blood
leads in countries that have eliminated lead
from gasoline (13), and the decline in the
levels ofpolychlorinated dioxins and diben-
zofurans in breast milk in Sweden (14),
attributable partly to the ban ofchlorinated
phenol herbicides.
OverallEthical Considerations. The
estimation of exposure is performed to
benefit the individual subject or popula-
tion, usually by subsequently reducing
their exposure to hazards. It is unethical to
perform a testing program merely for its
own sake, without having the goal of
reducing harmful exposures that may be
detected. Therefore, in a workplace, a bio-
logical monitoring program using markers
of exposure should be performed as part
of a comprehensive medical surveillance
program linked to an industrial hygiene
program capable of discovering and
eliminating hazards.
Zielhuis (10) cautioned that the results
of a screening examination must be exam-
ined in the light of many individual fac-
tors. In turn the physician must impart
objective information to the participant.
"In the perception ofthe examined subject,
biological sampling for assessment ofinter-
nal exposure, and henceforth ofhealth risk,
is not distinguished from assessment of
their health" (10). Individuals should be
informed of their health risks, along with
the degree ofuncertainty, regardless ofthe
technologic and economic consequences.
Some question the ethics ofbiological
monitoring for exposure, arguing that
humans should not be the guinea pigs or
the detectors of their own exposure.
However, biological monitoring offers the
advantage oftaking into account absorp-
tion by all routes (whereas air monitoring
would not detect potential exposure by
other routes). We caution that biological
monitoring can be an adjunct, but it can-
not substitute for environmental monitoring
and controls. [See below and Soskolne
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Table 1. Examples of biological exposure markers.
Agent
Aniline
Benzene
Cadmium
Carbon disulfide
Chlorobenzene
Chromium VI
N,N-Dimethylformamide
Ethylbenzene
Fluorides
Furfural
n-Hexane
Lead
Methanol
Methemoglobin inducers
Methyl chloroform
Methyl ethyl ketone
Nitrobenzene
Organophosphates
Parathion
Pentachlorophenol (PCP)
Styrene
Toluene
Trichloroethylene (TCE)
Xylenes
Exposure marker
Total p-aminophenol in urine; methemoglobin in blood
Total phenol or muconic acid in urine; benzene in expired air
Cadmium in urine or blood
2-Thiothiazolidine-4-carboxylic acid in urine; CO in end-expired air
Total 4-chlorocatechol orp-chlorophenol in urine
Total Cr in urine
N-Methylformamide in urine
Mandelic acid in urine or ethylbenzene in end-expired air
Urinaryfluoride
Total furoic acid in urine
2,5-Hexanedione in urine orn-hexane in expired air
Lead in blood or urine, ZPP
Methanol orformic acid in urine
Methemoglobin
Methyl chloroform in end-expired air ortrichloroacetic acid in blood or urine
Urinary methyl ethyl ketone
Total p-nitrophenol in urine or methemoglobin in blood
Red cell or serum cholinesterase activity
Total p-nitrophenol in urine or RBC cholinesterase
Total PCP in urine orfree PCP in plasma
Mandelic acid in urine, styrene in blood; phenylglyoxylic acid in urine
Hippuric acid in urine; toluene in blood or end-expired air
Trichloracetic acid in urine; TCA ortrichlorocethanol in blood; TCE in end-expired air
Methylhippuric acids in urine
(15) elsewhere in this issue for a further
discussion ofethical issues.]
Examples ofBiological Monitoring
for SelecedAgents (Table 1)
Heavy Metals. Most heavy metals are of
toxicologic concern, although some are
essential trace elements in humans as well.
Since these elements are not metabolized,
they can be tracked in the body, and can
be measured in various body compart-
ments and fluids. A variety ofstandardized
analytic procedures are described in readily
available references (16). Most ofthese are
analyzed with atomic absorption spec-
trophotometry (AAS), usually using a
graphite furnace as the source. Flame pho-
tometry works with higher concentrations
of metals. Mercury is usually measured
with a cold vapor technique.
LEAD. A variety oftests oflead exposure
and early effects have been used, including:
6-ALA in urine, 6-ALA dehydratase activity
in red blood cells, free erythrocyte pro-
tophorporin or ZPP in blood (still widely
used), urinary coproporphyrin (very limited
use), and blood lead (the standard measure).
The measurement ofblood lead is con-
sidered the best sampling approach for both
adults and children (17). Analysis for pop-
ulations with negligible lead exposure (no
occupational exposure in countries without
leaded gasoline) requires the sensitivity of
graphite furnace AAS; this is currently
the most widely used instrument for any
population, although anodic stripping
voltammetry is also used. In the absence of
this capability, excessive lead exposure can
be detected by measuring ZPP in a finger-
stick blood sample with a portable fluo-
rometer. Alternative methods still available
in some laboratories include measuring the
urinary excretion of6-ALA.
These measurements reflect relatively
recent and ongoing exposure. They do not
provide information regarding the body
burden or effects oflong-term accumula-
tion. The challenge test, which uses a dose
of a chelating agent (usually EDTA) and
monitors urinary lead excretion in the fol-
lowing 24 hr, provides an estimate of the
amount oflead that can be mobilized and
is used to judge whether chelation will be
effective. The chelation test carries a level
ofrisk, including the mobilization oflarge
amounts oflead which can then reach the
brain and kidneys.
The past decade has seen the develop-
ment of in vivo X-ray fluorescence (XRF)
ofbone as a way of measuring the relative
concentration of lead stored in the skele-
ton. Although increasingly available, the
technique is still under development, and
there is not adequate concordance among
laboratories (18). Two types of machines
are used, the K-wave and L-wave sources,
which differ in their penetration and
apparently in the precision of measure-
ments. Almost all machines in use today
employ K-wave XRF.
An example of using blood lead as a
marker ofexposure and susceptibility is a
recent study in Mexico. Romieu et al. (19)
found a significant correlation among the
lead content of ceramics used to prepare
food, the soil lead on children's hands, and
the children's blood lead; yet all ofthe envi-
ronmental variables explained only 19% of
the variance in blood lead. Thus even
assuming that there are uncertainties in
measurement ofthe independent variables,
this leaves tremendous room for individual
variability in the uptake and distribution of
inorganic lead in these children. Thus blood
lead identifies variation in susceptibility as
well as exposure among these children.
Analysis oflead in urine is ofrelatively
little value for quantifying exposure, even
in those with organolead exposure.
Many studies have shown that there is a
low correlation between lead in blood and
lead in air, due in part to the sampling
duration; concurrent exposures through
water, diet or other jobs; alternative routes
of exposure (ingestion); variations in the
use of protective equipment; variations in
circumstances ofexposure, including respi-
ratory rate, exercise, and other microniche
characteristics; and individual variation of
either a genetic or epigenetic nature (17).
MERCURY. The uptake, toxicokinetics,
and end points associated with organic mer-
curials (particularly methyl mercury) differ
greatly from those associated with inorganic
mercurials. Inorganic mercury is excreted
mainly in urine, organic mercury mainly in
feces. Both mercurials can be deposited in
hair. Accordingly, inorganic exposure is usu-
ally monitored with urinary mercury,
although blood mercury testing is also use-
ful and helps distinguish exposure within
the past week from that occurring in the
past month. Blood mercury is used to assess
organic mercury exposure. When dietary
exposure (especially fish consumption) is the
source ofmercury, it is usually not necessary
to speciate the mercury, since almost all of
the mercury is methyl mercury. There is a
strong correlation between either blood or
urine mercuryand air mercury (20).
Hair mercury is useful for screening
populations. The digestion ofhair, however,
causes difficulties in some laboratories (21).
Urinary mercury testing is mainly used for
occupational exposure or for residential
exposure to metallic (elemental) mercury.
CADMIUM. Cadmium is usually
measured in blood or urine by graphite fur-
nace AAS. Lauwerys et al. (7) documented
the relationship between exposure and
blood levels ofcadmium in humans. Many
Environmental Health Perspectives * Vol 105, Supplement 4 * June 1997 705BARRETT ETAL.
sources recommend the concomitant
measurement ofP2-microglobulin, but that
marker ofrenal tubular damage is insensi-
tive and should not be relied on. By the
time it becomes elevated, significant kidney
damage has occurred. However, a variety
of new tubular markers such as retinal
binding protein (RBP) and N-acetyl-p-D-
glucosaminidase (NAG) are more sensitive
but not more specific (22).
The body burden ofcadmium has been
measured by neutron activation in vivo
(23), but this is a highly specialized tech-
nique ofonly research application.
Pesticides. Pesticides include any sub-
stance or mixture that destroys or controls
plant or animal pests or vectors ofdisease.
"Pesticide" is a broad term including, in
addition to pesticides, a variety ofbiocides
(fungicides, herbicides, acaricides, mollusci-
cides, rodenticides, etc.) Pesticides remain a
global occupational health problem (24).
Some pesticides, such as the organo-
phosphates, are short-lived both in the
environment and in the body, and it is
possible to detect only acute exposure (by
measuring a metabolite) or recent exposure
(past 3 months) by measuring cholines-
terase levels. Chlorinated hydrocarbon
pesticides are persistent both in the envi-
ronment and in the body and can be mea-
sured for many months or years after
exposure has terminated (25,26).
PESTICIDE EXPOSURE. Absorption
resulting from dermal exposure is the most
important route of uptake for pesticide-
exposed workers, while ingestion is the
most important nonoccupational route.
Within the body, the pesticide may be
eliminated or transferred to a target,
unchanged or after metabolism. Organo-
phosphates are typically broken down
rapidly, while many organochlorine pesti-
cides are stored in the fat. The actual pesti-
cide exposure (uptake) can be measured by
biological monitoring ofhuman tissues and
body fluids. Insecticides and their metabo-
lites can be measured after occupational
exposures (26-29).
WHERE TO MEASURE VARIOUS
PESTICIDES. Different sampling approaches
are required for different classes ofpesti-
cide. Examples include the measurement of
dialkylphosphates in urine after exposure to
organophosphorus insecticides (27), of
p-nitrophenol after exposure to parathion
and methylparathion (28), and of 1-naph-
thol after exposure to carbaryl (29). Altered
liver enzyme activities have been reported
among pesticide workers exposed to
organophosphorus pesticides alone or in
combination with organochlorine or other
pesticides (30). Monitoring changes in
vitamin K levels is useful for identifying
exposure to anticoagulant rodenticides (31).
Adducts to hemoglobin have been
detected with several pesticides (32). The
advantages ofsuch measurements include
the possibility of assessing dose closer to
the target, ofassessing individual capacity
to form electrophiles, and ofextrapolating
data on toxicity more easily across species.
When the mechanism ofaction ofa pesti-
cide is understood, more specific markers
can be used (30).
ORGANOCHLORINES. Certain organo-
chlorine (OC) pesticides are highly persis-
tent. Although DDT is metabolized to DDE
and DDD, these metabolites persist in the
body fat for many years after exposure. They
can be detected at much lower levels in
serum. The reported levels in fatvaryamong
countries, the highest levels ofDDT being
found in countries where the compound is
still used. Fat biopsies are not suitable for
routine screening ofpesticide exposure.
Some studies ofthe concentration of
pesticides in human milk are summarized
by Anwar (26). The contaminants found
most frequently in human milk have been
DDT, its main metabolite DDE, hexa-
chlorobenzene, hexachlorocyclohexane,
dieldrin, heptachlor epoxide, and the non-
pesticide polychlorinated biphenyls (33).
ORGANOPHOSPHATES. Whereas persis-
tent organochlorine pesticides tend to have
relatively low human toxicity, the organo-
phosphates (OP) are highly toxic to humans
and are responsible for many deaths
around the world. These compounds bind
various cholinesterase enzymes, thereby
interfering with transmission in the ner-
vous system. A widely used biochemical
biomarker is cholinesterase depression. It is
frequently used in occupational health as a
marker of OP exposure and is regularly
used clinically as a marker of OP effect.
With a specific antibody it is possible to
measure the concentration ofa particular
esterase in plasma or serum. Diagnostic
kits to measure specific activities ofblood
esterases are being developed for use in the
field (30). However, it is essential that the
workers with potential exposure have two
baseline cholinesterase determinations,
since cholinesterase activity varies greatly
between individuals and within the same
individual over time (21,34).
Further markers in pesticide application
workers are described byAnwar (26).
Polycyclic Aromatic Hydrocarbons.
PAH are usually present in complex
mixtures of 3- to 6-ring compounds, of
which hundreds of congeners may be
present in various proportions. Analysis
is usually by gas or liquid chromatogra-
phy, where selected compounds, such as
benzo[a]pyrene (B[a]P) are quantified.
Biological methods have been devel-
oped to measure 1-hydroxypyrene (1-HP),
a metabolite of pyrene, in urine. 1-
Hydroxypyrene is a prevalent species in
PAH mixtures. It is excreted in the urine
and is a good biomarker of exposure to
PAH (35). An advantage is that urine can
be stored for at least a year frozen at -20°C
without preservative. After hydrolysis
and cleanup, the 1-HP is extracted and
analyzed on high performance liquid
chromatography (HPLC). The result is
expressed as pmols/mol ofcreatinine (35).
0vreb0 et al. (36) found levels up to
13.5 pmol/mol creatinine in coke oven
workers compared to 1.54 pmol/mol in the
surrounding community and up to only
0.2 pmol/mol in a control area.
Adducts ofhemoglobin or albumin are
measured after hydrolytic cleavage ofPAH
from the protein, followed byquantification
by mass spectrometry. DNA adducts are
measured by the 32P-posdabeling technique
and by immunoassay. Neither of these
techniques quantifies individual PAHs.
Jongeneelen (37) studied the S9 super-
natant fraction ofliver samples from 15 kid-
ney transplant donors for variation in PAH
metabolism in vitro. 1-Hydroxypyrene was
the major metabolite ofpyrene and 3-OH-
B[a]P was the major metabolite ofB[a]P.
The Vmax for B[a]P and for purine were
highly correlated. They found individual
variation in the Vmax and the apparent
affinity for the substrates. The Vmax for
B[a]P ranged from 0.002 to 0.710, with a
geometric mean of0.012.
Volatile Organies. Ethylene oxide is
discussed here as an example of a volatile
organic compound. Ethylene oxide is used
as sterilant in hospitals. It is also the princi-
ple metabolite ofethene, a precursor to
polyethylene plastics and other synthetic
chemicals. Ethylene oxide can be measured
by gas chromatography in air or biological
specimens. Ethylene oxide reacts in the
body with hemoglobin; N-terminal valine
may be released by a modified Edman
degradation process and measured by
gas chromatography-mass spectrometry.
DNA adducts can be measured by a
number oftechniques [above; Hemminki
(11)], including 32P-postlabeling mass
spectrometry and liquid chromatography/
electrochemical detection.
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Ionizing Radiation. Various cytoge-
netic techniques have been used extensively
to study populations exposed to ionizing
radiation, most notably the survivors ofthe
bombing of Hiroshima and Nagasaki.
Giemsa-banding techniques are labor
intensive and provide a resolution ofabout
1 million base pairs. They give information
on the frequency ofchromosomal aberra-
tions: breaks, dislocations, deletions, and
translocations. The fluorescent in situ
hybridization (FISH) technique (38) corre-
lates well with traditional chromosomal
aberration analysis and allows a more rapid
screening of individual samples for dose
reconstruction. This is also an effect
marker. Reciprocal translocations are
apparently permanent, hence are poten-
tially useful for dose reconstruction even
years after the exposure event. The use of
hypoxanthine phosphoribosyltransferase
(HPRT) mutants and other molecular bio-
logic approaches to detect gene alteration,
including radiation specific lesions in DNA
(39) is dealtwith below.
SamplingConsiderations
Toxiokinetics TheImportanee ofTiming.
Many endogenous chemicals and probably
also xenobiotics do not maintain a constant
level in the body but undergo diurnal varia-
tion, sometimes in a deterministic fashion.
Therefore it is important to standardize
techniques by sampling at one time ofday.
However, it is also important to understand
the time course of excretion, which is not
always a uniphasic half-life (negative expo-
nential curve) but may be biphasic or
triphasic with an initial rapid elimination
followed by much slower elimination. Ifa
substance is mainly excreted within 24 to
48 hr, it is possible only to monitor for
acute exposure. Even for substances with a
half-life of 6 to 12 months, it may be
impossible to reconstruct the exposure that
mayhave occurred in years past.
Condusions andRecommendations
Biological monitoring ofexposure can play
an important role in the detection of
exposed individuals or groups at an early
stage before significant or irreversible
adverse effects have occurred. Biological
markers of exposure also play a role in
quantifying or classifying exposure for epi-
demiologic studies. Biological monitoring is
also useful in identifying variations in sus-
ceptibility among members ofa population.
It is important that any biological moni-
toring for exposure markers be conducted
as part of a comprehensive framework
that includes steps for intervening and
reducing any hazards that are identified. A
screening program should meet the criteria
proposed by WHO. The information
from such programs should be shared with
the stakeholders.
Biological Markers of Effect
Definitions
The International Programme on Chemical
Safety has defined a biomarker ofeffect as
"A measurable biochemical, physiological,
behavioral or other alteration within an
organism that, depending upon the magni-
tude, can be recognized as associated with
an established or possible health impairment
or disease" (1).
This is a very broad definition. Such
biomarkers of effect can be elicited as a
result ofinteraction ofthe organism with a
host of different environmental factors
(including chemical, physical, and biologic
agents); this definition encompasses bio-
markers ofeffect at the level ofthe whole
organism, at the level oforgan function, at
the level of tissue and individual cells, and
at the subcellular level. For example, the
results of neuropsychologic tests may be
considered biomarkers ofbehavioral effects
ofthe organism which may be induced by
solvent exposures. Spirometry results may
be considered biomarkers ofphysiological
effects on the respiratory system which
may be induced by fibrogenic dust expo-
sures. Sperm counts may be considered
biomarkers ofeffect on reproductive cells
which may be induced by exposure to syn-
thetic estrogenic compounds. There are
many other similar examples ofbiomarkers
at these levels in almost all systems ofthe
body, induding biomarkers ofhematologi-
cal toxicity, nephrotoxicity, hepatotoxicity,
immunotoxicity, neurotoxicity, pulmonary
toxicity, and reproductive and develop-
mental toxicity (1). These will not be con-
sidered further here, but rather this review
will focus on biomarkers ofeffect at the
subcellular level, particularly at the chro-
mosomal and molecular level, which are
particularly useful in assessing susceptibil-
ity. These include biomarkers at the
genomic level, such as cytogenetic alter-
ations and gene mutations, and biomarkers
ofgene expression, such as messenger RNA
and proteins. Some assays ofprotein func-
tion, such as enzymatic activity, could be
included in this category but could a,lso be
considered as biomarkers ofexposure (e.g.,
cholinesterase activity in response to OP
exposure), and thus they will not be
included here. Biomarkers at the genomic
level or at the level ofgene expression have
been most strongly associated with the risk
for cancer, although in selected instances
they may also be associated with other dis-
ease end points. Therefore, in general, we
will be concerned here with subcellular bio-
markers of effect that are believed to be
associatedwith cancer. We will examine the
methodologies employed with reference to
the objectives oftheir use, their potential
uses, and theiradvantages and limitations.
Because in many instances, these
biomarkers ofeffect are believed to repre-
sent events in a causal pathway to disease,
their occurrence may be viewed as indica-
tive of an acquired susceptibility for that
disease. This is in distinction to the bio-
markers ofsusceptibility per se, which in
many cases represent indicators of inher-
ited susceptibility to disease due to their
influence on steps in the causal pathway.
Biological markers ofeffect, as indicators
ofacquired susceptibility for disease, have
the theoretical potential to exhibit predic-
tive value in identifying individuals who
could develop disease at some point in the
future or in determining the likely disease
progression in terms ofseverity and prog-
nosis once disease has occurred. In addi-
tion, biomarkers of effect, because they
occur quite far along the pathway between
exposure and disease outcome, essentially
provide an effective integration of the
influence ofbiomarkers ofsusceptibility
for all preceding steps in the causal path-
way and are thus a summary marker for
susceptibility to that point.
CytogeneticMarkers
In humans, cytogenetic alterations are
most often analyzed microscopically from
peripheral lymphocytes after they have
been stimulated to divide in culture by a
mitogen (40). Lymphocytes are used as a
surrogate for the actual target tissues of
genotoxic carcinogens. Some cytogenetic
end points (micronuclei, numerical aberra-
tions) can also be studied in interphase
cells from target tissues or proximate target
tissues, such as exfoliated cells from buccal,
nasal, urothelial, bronchial or esophageal
epithelium (41,42). Specimens can also be
obtained from hair bulbs. In special cases,
for instance, in connection with accidental
exposures, dividing cells from bone mar-
row maybe available. Furthermore, cytoge-
netic biomarkers can be studied from
samples collected for prenatal diagnosis
(amniocytes or chorionic villus cells).
Effects on germ cells can be examined from
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semen specimens (43). Fresh samples are
required in most cases, but preservation by
freezing or fixation is possible for several of
the cytogenetic techniques. The analysis of
cytogenetic end points from such samples
is used to show exposure to genotoxic car-
cinogens and may have value in the identi-
fication of groups of people at increased
risk ofcancer (44,45). Cells from different
individuals can be challenged with geno-
toxic agents in vitro, which in some cases
may enable the recognition of sensitive
individuals (46,47).
Chromosome Aberrations. Chromo-
some aberrations (CAs) are structural
alterations, breaks and rearrangements, in
chromosomes, usually observed in meta-
phase-blocked cells using conventional
microscopy (40). Chromosome-type
rearrangements, such as translocations and
dicentrics inspected in biological dosimetry
of radiation, can also be analyzed using
chromosome painting based on FISH with
chromosome-specific DNA probe libraries
(48). This approach has enabled the recog-
nition of new types ofcomplex chromo-
some rearrangements that have not been
detectable with conventional cytogenetic
techniques. Recently, a simplified FISH
method to detect chromosome breakage
and alterations of chromosome number,
using tandem DNA probes specific for a
region in chromosome number 1, was
reported (49). FISH has also been applied
to study numerical chromosome aberra-
tions of specific chromosomes (50).
Polymerase chain reaction (PCR)-based
methods for the analysis of lymphocyte-
specific illegitimate chromosome recombi-
nation involving human immunoglobulin
or immune receptor loci and considered to
reflect genetic instability have also been
described (51,52). In two recent, indepen-
dent reports, increased rates of CA in
peripheral lymphocytes were shown to be
associated with later development ofcancer
(44,45). Thus, the analysis of CAs is
presently regarded as the cytogenetic
method of choice in studies of human
exposure to genotoxic carcinogens. In vivo
inducers ofCAs in humans include, among
others, ionizing radiation, alkylating cyto-
statics, tobacco smoking, benzene, and
styrene. Besides smoking, factors such as
age, gender, and diagnostic and therapeutic
X-rays are usually taken into account as
possible confounders. In vitro challenging
oflymphocytes from healthy individuals
with genotoxins has revealed individual
differences in CA response to some geno-
toxic agents (53,54). The reasons for such
differences are unknown, except for
1,2:3,4-diepoxybutane, where an associa-
tion probably exists with the deficiency of
glutathione S-transferase TI (GSTT1)
(46,47,55). Among butadiene-exposed
chemical workers, GSTTI null individuals
also had an elevated rate of chromosome
aberrations in peripheral lymphocytes in
vivo (56). On the other hand, the lack of
GSTM1 has been associated with elevated
CA frequencies in smokers and in bus
drivers (57).
Sister Chromatid Exchanges. Sister
chromatid exchanges (SCE) represent sym-
metrical exchanges of DNA segments
between the sister chromatids of a dupli-
cated metaphase chromosome (58). In
lymphocytes ofhumans, tobacco smoking,
alkylating cytostatics, and ethylene oxide
are well documented SCE inducers.
Factors to be controlled in the analysis of
SCEs include age, gender, and life style.
Individuals with enhanced in vitro SCE
response to some genotoxins have been
described and, in some cases, this has been
associated with certain metabolic genotypes
or phenotypes (46,47,50,59-66). For
example, individuals sensitive to in vitro
SCE induction by 1,2:3,4-diepoxybutane
were recently found to be deficient of
GSTT1 (46,47,62,64,66). Such people also
show elevated baseline frequencies ofSCEs
in their peripheral lymphocytes (47,62,67).
SCEs were not, however, elevated in GS7TJ
null individuals exposed to butadiene (62).
Increased SCE rates have also been indi-
cated in relation to the GSTMJ null geno-
type and smoking (68) and deficiency of
the low Km aldehyde dehydrogenase and
alcohol consumption (69).
Micronuclei. Micronuclei (MN) are
small additional nuclei observable in inter-
phase cells. Micronucleus induction can be
triggered by either clastogens or agents that
influence the mitotic apparatus, such as
spindle poisons (70,71). Micronuclei can
also be scored in exfoliated cells ofbuccal,
nasal, or urothelial mucosa (41). The pres-
ence ofwhole chromosomes in MN can be
checked by identifying centromeric DNA
sequences (using FISH) or kinetochore
proteins in the MN (72,73). In vivo,
increased MN frequencies in lymphocytes
have been associated with exposure to ion-
izing radiation, aging, and gender (74). In
women, the influence of age on the fre-
quency of MN in lymphocytes has been
relate,d to an increased inclusion of the X-
chromosome in MN (75,76), while in
men the Y-chromosome appears to be
responsible for a part ofthis effect (77). In
buccal or nasal mucosa, MN induction has
clearly been shown for, e.g., various ethnic
chewing habits (3) and exposure to
formaldehyde (78). The MN analysis has
given negative results in several studies in
which another biomarker of genotoxic
exposure has been positive. As MN can
originate from chromosomal fragments
and whole chromosomes, the number of
cells presently examined may not be
enough to reveal the relatively small effects
usually expected in exposed humans. The
identification of the centromeric contents
of MN and automated analysis may
improve the specificity and sensitivity of
the MN assay oflymphocytes.
General Considerations. At the
population level, structural CA appears to
have predictive value for later development
ofcancer. As similar associations have not
been detected for other cytogenetic end-
points, the analysis ofCA appears to be, at
present, the cytogenetic method ofchoice
in studies ofcytogenetic alterations in lym-
phocytes. However, the sensitivity of the
assay does not allow evaluation of cancer
risk based on individual values. Analysis of
an in vitro cytogenetic response ofhuman
cells to genotoxins may, in some cases, be
used to identify susceptible individuals,
especially when genetic polymorphisms are
taken into account. In biological dosimetry
ofradiation exposure, the analysis ofchro-
mosome-type aberrations has been used as
the basis for individual dose estimates.
Chromosome painting by FISH is becom-
ing the new tool in the biological dosimetry
ofradiation; the applicability oftechniques
based on FISH and PCR for the identifica-
tion ofspecific chromosome alterations for
studies of chemical genotoxins should be
evaluated. The MN assay combined with
FISH analysis ofcentromeres in MN may
offer an easier technique to score CA, espe-
cially in target tissues or proximate target
tissue. Because each biomarker depicts a
different phenomenon, the use ofvarious
exposure and effect biomarkers together is
recommended in risk assessment. It is also a
useful approach for detecting patterns of
human susceptibility. The combination of
cytogenetic parameters and information on
metabolic genotypes or phenotypes is
expected to increase the sensitivity of the
cytogenetic assays and allow better under-
standing of the biological significance of
genetic polymorphisms (43). As some poly-
morphisms have been shown to influence
basic or induced levels of cytogenetic
damage, information on the genotypes or
phenotypes of the individuals studied is
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becoming important when these end
points are used as biomarkers. Automation
and analysis techniques utilizing FISH
offer faster and easier approaches to detect
cytogenetic alterations.
Markers ofGeneMutations
Somatic Gene Mutations in Surrogate
Tissues. The detection ofmutations in the
HPRTgene has been used in experimental
mutagenicity studies of mammalian cells,
and it is also the most extensively employed
assay for human gene somatic mutations in
vivo. In humans, HPRTmutations are
examined in lymphocytes, and the standard
assay involves T-lymphocyte cloning for
phenotypic selection of6-thioguanine-resis-
tant mutant cells. With the development of
PCR-based techniques, further molecular
characterization ofthe mutations present in
the T-cell clones has also become possible.
Such studies have shown, for instance, a
clear difference in mutation spectrum
between "spontaneous" mutations occurring
early in human development and mutations
acquired later in life (79). Studies ofhuman
lymphocytes in vitroare also considered use-
ful, as they provide information on HPRT
mutation spectra obtained after exposure to
specific carcinogens in controlled condi-
tions. Several studies have been carried out
on HPRT-mutant lymphocytes in human
populations exposed to various genotoxic
agents, as reviewed by Cole and Skopek
(80) and briefly described by Hemminki
(11). Only a few studies have thus far tried
to correlate HPRTmutations with other
measures ofexposure and susceptibility. In a
study ofoccupational exposure in a foundry,
the frequencies of HPRT-mutant T-lym-
phocytes correlated with the level ofaro-
matic DNA adducts (81,82). In a recent
study on garage workers, a correlation was
found between aromatic DNA adducts and
mutation frequency at the individual level;
genotypes of two xenobiotic-metabolizing
genes (GSTMI and NAT2), alone or com-
bined, did not influence HPRTmutation
frequency (83).
The glycophorin A (GPA) assay is
another in vivo method for the detection of
somatic mutations to study the potential
effects ofexposure to chemical and physical
mutagens (84,85). The assay is based on
the autosomal GPA locus that encodes the
cell surface sialoglycoprotein expressed in
the erythrocytic lineage and responsible for
the M,N blood group. It uses immuno-
labeling and flow cytometry to enumerate,
in peripheral blood samples of M/N
heterozygotes, erythrocyte variants reflecting
mutations in the GPA locus. Most of the
variants are considered to derive from
mutations that occurred in bone marrow
stem cells and are therefore permanent,
depicting lifetime accumulation of muta-
tions. The GPA assay has been automated
and is thus easy, fast, and cheap to run.
The main limitations are that only one half
of the human population (M/N heterozy-
gotes) can be studied and an expensive flow
cytometer is required. As erythrocytes have
no nuclei, the variant cells cannot be clon-
ally expanded and the mutations cannot be
characterized at the molecular level.
Both the HPRTand GPA mutation
assays show a small number ofpeople with
exceptionally high mutant frequencies in
healthy subjects (86). While at least part of
such high frequencies are due to clonal
expansion ofa few original mutations, some
of them might indicate individuals of
enhanced susceptibility. In a study ofGPA
mutations in reinforced plastics workers,
the high frequency individuals were primar-
ily smokers or ex-smokers (87). Recently it
was shown that in smokers significantly ele-
vated NN variant frequency was associated
with GSTTI null genotype (88).
Gene Mutations in Target Tissue.
Knowledge on gene mutations from other
tissue than peripheral blood and lympho-
cytes is sparse. This relates to problems in
availability ofsamples and difficulties in
developing methods suitable for detecting
mutations occurring at a low frequency.
Growing cells under in vitro conditions cir-
cumvents the problem with lymphocytes.
Somatic mutations have been detected in
genes related to human disease and partic-
ularly in cancer-related genes (protoonco-
genes and tumor suppressor genes). In
most cases somatic mutations in disease-
related genes do not give rise to any func-
tional change in the cell, which would
allow its isolation or expansion in vitro. In
the case ofcancer tissue, malignant growth
involves clonal expansion of cells, which
allows detection ofmutations by the meth-
ods presently available. The methods
appear to work best and most reproducibly
on fresh frozen tissue, but in many
instances only preserved tissue is available.
Mutations in oncogenes and tumor
suppressor genes are most common in
many types ofhuman cancer. In the con-
text of external exposure to carcinogens,
the rasgenes have been shown to be muta-
tionally activated in a number of environ-
mental cancers in humans (89), and. in a
carcinogen-specific manner in animal
studies (90). Since thep53tumor suppressor
gene is among the most frequently altered
genes in human cancer, molecular analysis
ofits mutational spectra has been used as a
clue to cancer etiology and mechanisms of
carcinogenesis (91,92). In the p53 gene,
DNA sequences corresponding to the
highly conserved domains of the protein
have been identified as a "hot spot" region
for mutations. A majority of mutations
identified in these genes in human cancers
are missense mutations, making them suit-
able targets for such analysis. The expo-
sure-related nature ofp53 mutations has
been proposed in many studies on various
forms of human cancers (91-94). Well-
known examples of this are nonmelanoma
skin cancer associated with exposure to
sunlight (UVB) as well as hepatocellular
carcinoma related to dietary exposure to
the mycotoxin aflatoxin B1 (AFB1) (92).
With the highly sensitive mutation detec-
tion assays it has been possible to investi-
gate whether the suggested causative
carcinogens (AFB1, UVB) induce similar
kinds ofmutations in human cells in vitro.
In the case ofAFB1, the results were in
agreement with the etiological role of
AFB1, although other types of mutations
were also seen (95). In nonmalignant
human liver tissue, the frequency of the
specific AGG to AGT mutation at codon
249 was found to parallel the level ofAFB1
exposure in the geographical areas where
the patients lived (96). For UVB exposure,
the experimental work on human skin
fibroblasts did not find the tandem double
CC to TT mutations seen frequently in
skin cancer (97). A relationship between
certain types of ras mutations orp53 muta-
tions and occupational exposure to agents
like solvents, vinyl chloride monomer, some
bladder carcinogens, and radon has been
suggested (98-100). In addition, smoking
has been associated with increased preva-
lence ofp53mutations in some tumors, and
certain types ofbase substitutions have been
linked with exposure to tobacco smoke
(101,102). Recently, two studies have
reported a higher frequency ofp53 muta-
tions in lung cancer patients with the at risk
genotype ofGSTMI gene (103-105).
Studies on prognostic significance of
p53 protein overexpression (determined
immunohistochemically) or mutation have
suggested that accumulation ofthe mutant
protein may predict poor survival in many
cancer types (92).
Methodological Considerations. An
array ofmethods has been used for detection
ofpoint mutations in unknown positions
of the target gene. Most of them initially
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used radioactive labeling but alternative
techniques have been developed. One of
the first techniques available was the RNase
mismatch cleavage analysis method (106).
Methods relying on chemical modification
ofmismatched nucleotides, by either car-
bodiimide or hydroxylamine and osmium
tetroxide (chemical cleavage ofmismatch),
have been developed; they use mutation
detection mainly in genes ofinherited dis-
eases (107). Two assays used widely in
mutation detection in association with
inherited diseases, genetic polymorphisms,
and also for somatic mutations in tumor
tissue are single-strand conformation poly-
morphism (SSCP) and denaturing gradient
gel electrophoresis (DGGE). SSCP assay is
based on conformational changes in DNA
due to sequence alterations (108,109).
SSCP has been successfully used for detec-
tion of DNA alterations of many cancer-
related genes in human cancer (ras, p53,
RB, for example). It is estimated to yield
over 90% efficiency in detecting single base
substitutions in sequences of300 bp or less
in length (109,110). It is also well suited
for detection ofpolymorphic alleles ofvari-
ous genes (109). DGGE separates DNA
molecules based on their sequence-deter-
mined ability to melt (separate partially) in
longer fragments (low- and high-tempera-
ture melting domains) (111). DGGE sepa-
rates physically wild-type DNA from
mutant molecules, and under appropriate
conditions all single-base substitutions,
frameshifts, and deletions less than about
10 bp can be resolved from the wild-type
DNA (112). DGGE, or its application
called constant gradient gel electrophoresis
(CDGE) (113), has been used to studyboth
germline and somatic mutations in many
human genes. These include mutations in
cancer-related genes, human ras and p53
genes, as well as chemically induced muta-
tions ofHPRTgene in human lymphocytes
in vitro (112). More recently, a capillary
electrophoresis technique has been applied
for CDGE (114).
For detection of known mutations in
certain sites of a gene, two much-applied
methods include allele-specific oligonu-
cleotide hybridization and genotypic muta-
tion analysis by restriction fragment length
polymorphism (RFLP)/PCR method.
Allele-specific oligonucleotide hybridization
uses labeled probes which are hybridized
to PCR-amplified genomic DNA. It has
especially been used in studies on ras gene
mutations in various human cancers
(89,115). More recendy, many assays rely-
ing on recognition ofa certain restriction
site which either is present in the wild-type
sequence or results from a mutation have
been developed. Ofthese, one ofthe most
sensitive and perhaps most promising for
molecular toxicology purposes is the
RFLP/PCR assay for detection ofcodon
12 mutations in the human H-rasgene and
codon 247 to 250 mutations in the human
p53tumor suppressor gene (116,117). The
method is very sensitive and suitable for
detection ofvery low frequency mutations,
such as those in premalignant or in normal
cells after chemical treatment in vitro.
They are, however, limited to a single base
substitution at a certain codon.
DNA sequencing based on dideoxy-
mediated chain termination reaction (118)
can be performed also after in vitroamplifi-
cation of the DNA template by PCR.
Direct sequencing of PCR amplification
products is thus one method ofchoice for
mutation analysis; it is perhaps more labor
intensive when performed manuallybut has
been automated (119). Methods using
solid phase support in sequencing are being
used increasingly (120). Sequencing has of
course the advantage ofgiving precise infor-
mation on the sequence alterations unlike
some other methods (SSCP, DGGE). For
targeted use, an application called solid-
phase minisequencing has been developed
(121). However, direct sequencing ofgeno-
mic DNA ofpoor quality may be problem-
atic (fixed and paraffin-embedded tissue
samples) and other methods are better
suited in such instances.
Markers ofGeneExpression
mRNA Expression. Markers of gene
expression include assays for detection of
mRNA or for detection ofproteins. Many
of the assays for mRNA employ method-
ologies similar to those used for DNA
analysis noted above. In most cases, the
assays have been used for the examination
ofdiseased tissue (e.g., cancer tissue) in the
target organ. This poses problems ofacces-
sibility. In addition, mRNA has very lim-
ited stability, and, therefore, tissue samples
must be obtained fresh and processed quite
rapidly so that the mRNA is preserved.
With the appropriate oligonucleotide
probes, the presence of mRNA in tissue
can be detected by in situ hybridization.
For example, differences in mRNA for
oncogenes may be detectable between
cancer tissue and adjacent normal tissue
(122). Other disease end points may also
be relevant. For example, in situ hybridiza-
tion can detect increases in mRNA for
growth factors, such as platelet-derived
growth factor and transforming growth
factor-,, in relation to the stimulation of
cell growth and the development offibrosis
resulting from asbestos (123). Alternately,
tissue can be analyzed for mRNA expres-
sion by isolation ofmessage and amplifica-
tion by quantitative PCR followed by
Northern blot analysis (analogous to the
separation techniques of Southern blot
analysis for DNA by gel electrophoresis)
with appropriate oligonucleotide probes.
Quantitative PCR is considerably more
difficult to perform reliably compared to
qualitative PCR, adding further complexity
to this approach.
None of the approaches to mRNA
expression have been well developed for
routine application. Thus, among other
problems, there is generally little standard-
ization ofassay techniques, little definition
ofnormal values or values ofpathophysio-
logic significance, and little examination of
reproducibility, sensitivity, specificity and
predictive value ofthe tests in terms ofthe
occurrence ofor prognosis for disease state
(i.e., indication ofsusceptibility for devel-
opment or severity ofdisease). Given these
limitations and the other difficulties noted
above, it is probably unrealistic to expect
that gene expression by mRNA analysis
will be very useful as a biomarker ofeffect.
At any rate, the true index ofgene expres-
sion from the point ofview ofeffect in the
cell is at the protein level, not the mRNA
level, and it is not even clear that the two
always correlate. As noted below, detection
ofprotein expression has the potential to
avoid some of the problems inherent in
mRNA detection and is thus the more
attractive candidate for a biomarker ofgene
expression for many reasons.
Protein Expression. Methodologies for
examining gene expression by the detection
ofthe encoded proteins all depend on the
development of antibodies (either poly-
clonal or monoclonal) that are theoretically
specific for the identification ofthe protein
of interest. In many cases, however, the
specificity is only theoretical because there
is cross reactivity ofthe antibodywith simi-
lar epitopes in other, unrelated proteins,
raising the possibility offalse-positive tests.
Conversely, sensitivity of the antibody
detection (related to many factors, includ-
ing avidity and affinity for the epitope,
accessibility and stability ofthe epitope,
and the sensitivity ofthe secondary reaction
system used to identify the occurrence of
the antigen-antibody interaction) may be
insufficient to detect the antigen, leading to
false-negative tests. Monoclonal antibodies
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that are produced from a single cell that is
clonally expanded and producing an anti-
body for only a single epitope are more eas-
ily standardized. Polyclonal antibodies can
be variable and are thus more difficult to
standardize but may have the virtue of
reacting with several different epitopes on
the protein ofinterest, increasing the likeli-
hood of detection. Modifications of anti-
body applications that can improve the
results include confirmation ofthe molecu-
lar weight ofthe identified protein as con-
sistent with what is expected and the use of
more than one antibody probe to demon-
strate that the protein identified reacts with
all expected positive antibodies; it does not
react with negative antibodies.
For protein identification of gene
expression, antibodies can be used in tissue
analysis or in assays ofsurrogate sites such
as extracellular fluids. As with mRNA
analysis, tissue analysis for protein expres-
sion usually relies on diseased tissue (e.g.,
cancer tissue) in the target organ, although
in some cases the same analysis can be
applied to exfoliated cells, for example,
from the urothelium or the bronchial
epithelium (124). Tissue analysis can be
either in situ or in aggregate. In situ analy-
sis relies on the application ofthe appropri-
ate antibody in immunohistochemistry
either to fresh-frozen tissue sections or to
fixed, paraffin-embedded tissue sections.
The latter approach raises issues ofthe sta-
bility ofthe antigen with fixation and with
storage over time, which can vary with the
different proteins. Immunohistochemistry
allows for the localization of proteins of
interest within cells (e.g., the question of
whether the protein is identified at the sub-
cellular site one would expect) as well as
within the histology ofthe specimen (e.g.,
ifthe protein is identified in cancer tissue,
in precursor lesions, in apparently normal
adjacent tissue). Aggregate analysis oftissue
can be accomplished with fresh tissue spec-
imens by lysis of the cells and analysis of
the appropriate cellular fraction of the
lysate (125,126). Analysis ofcell lysate can
be performed with antibodies applied in
Western blotting (separation of the pro-
teins by gel electrophoresis followed by
antibody probing), which has the advan-
tage ofallowing molecular weight determi-
nation as a confirmatory indicator but
which can be laborious, difficult, and hard
to standardize. Alternately, analysis ofcell
lysate can be performed with antibodies
incorporated into an antigen-competition
or an immunosorbent assay, such as
radioimmunoasays or enzyme-linked
immunosorbent assays (ELISA), which are
generally easier, more rapid, and more eas-
ily standardized. Stepwise application of
assays can be employed, for example, in
which an ELISA may be used to screen
samples and Western blotting may be used
to confirm positive results.
Protein identification in extracellular
fluids can be similarly accomplished with
antibodies employed in Western blotting
or ELISA or related assays. This approach
is obviously more accessible and conve-
nient than relying on tissue, but it raises
issues such as whether extracellular fluid
protein levels accurately reflect cellular pro-
tein levels. Identification ofcertain proteins
in extracellular fluids, such as tumor-
associated antigens, has been well standard-
ized in convenient assays and widely
applied. Prostate-specific antigen (PSA) is a
good example (127,128). Even in these
cases, however, many important issues
remain unresolved. Tumor-associated anti-
gens like PSA maybe useful monitoring the
course of disease once identified and
treated, but the relationship to the patho-
physiology ofthe disease process remains
unclear and thus its utility in predicting
future occurrence of disease that will be
clinically significant in an individual is
unproven. Other proteins that represent
expression ofgenes in the presumed causal
pathway for disease, such as growth factors
and oncoproteins, can also be analyzedwith
antibody-based techniques in extracellular
fluids, as described in depth by Brandt-Rauf
(129). Unfortunately, these tests are not as
well developed as the others mentioned. In
general, they are not standardized; normal
values and values ofpathophysiologic sig-
nificance are not well defined; confounders
have not been identified; and sensitivity,
specificity, and predictive value as indica-
tors ofsusceptibility for disease occurrence
need to be more closely examined. Thus,
they are clearly not ready for routine use at
this time. As with all biomarkers ofgene
expression, additional research will be nec-
essary to more clearly define their advan-
tages and limitations and to determine their
potential uses.
Condusions andReconmendations
ConsiderationsforDeveloping Countries.
Little work has been done to monitor the
level of exposures and their effects on
human populations in developing countries
(130). Although trials have been done for
cytogenetic monitoring ofpopulations at
risk (42,131), more effort should be made
to improve the information concerning
human exposure possibilities and the
identification ofexposure-related diseases.
Simple cytogenetic techniques (such as
CAs, SCEs and MN) and simple gene
expression techniques (ELISA for protein
levels) can be applied for monitoring in
developing countries. More advanced mol-
ecular biomarkers (e.g., based on PCR and
gene sequencing) may be considered only if
the appropriate resources are available.
General Considerations. Most of
the biological markers of effect described
here are still experimental tools whose
utility remains to be established. For these
biomarkers, issues of assay validation,
QA/QC, and convenience and cost need to
be addressed. As noted above within the
context ofsusceptibility, one objective of
their use would be the identification of
individuals or groups who, by virtue ofthe
acquired susceptibility to the effect, are
likely to develop disease. Some examples,
such as the evidence that increased rates of
chromosomal aberrations are associated
with later development of cancer, suggest
that this may be possible, but in most cases
ofbiomarkers ofeffect, the predictive value
remains unproven.
Even ifpredictive value is ultimately
established, problems will remain. The util-
ity ofestablishing such susceptibility with-
out any way to alter it is ofquestionable
value. In some cases, the effects detected
may be irreversible, so effective secondary
prevention would be one important option.
In other cases, the effects detected may be
reversible (as with the reversion of SCE
rates following removal ofexposure to cyto-
static drugs), so that primary prevention
may be effective. At any rate, primary pre-
vention through the reduction or elimina-
tion ofthe exposure producing the effect is
always good policy, and secondary preven-
tive interventions or the use ofbiomarkers
to eliminate individuals from ongoing
exposure situations are not a substitute for
primarypreventive efforts.
Other important social, legal, and ethical
implications also derive from these aspects of
biomarkers ofeffect. Forexample, the know-
ledge oftruly predictive biomarkers ofeffect
could obviously be misused to detrimentally
affect the employability and insurability of
the individual concerned, compounding the
suffering induced by the psychological bur-
den ofthe knowledge. Furthermore, such
knowledge having a potentially adverse psy-
chological effect raises the issue ofwhether
the detection ofa biomarker ofeffect is itself
an impairment and perhaps a disability,
even without other demonstrable clinical
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effects. Could such an impairment/disability
be compensable under tort orworkers' com-
pensation laws? Would such an individual
be entitled to special considerations under
laws for protecting the disabled in employ-
ment and other societal circumstances? Prior
to the general use of biomarkers ofeffect,
such questions will have to be addressed.
Some general ethical aspects ofthese issues
are considered in more detail elsewhere in
this volume.
Other potential uses of biomarkers of
effect are in monitoring ofdisease progres-
sion and prognosis, and as adjuncts to
other biomarkers in providing refinements
of epidemiology and risk assessments. At
the very least, biomarkers ofeffect, as well
as other biomarkers, offer the opportunity
to provide scientific confirmation of pro-
posed exposure-disease pathways in vivo in
human populations. Biomarkers of effect
may be particularly useful for demonstrat-
ing the biologic influence of preceding
susceptibility factors (e.g., genetic poly-
morphisms of xenobiotic-metabolizing
enzymes). It should be noted once again,
however, that at this time these biomarkers
of effect should only be employed in the
context ofcarefully designed studies with
all due attention to the rights and concerns
ofthe human subjects involved. Neverthe-
less, we believe that research on biomarkers
ofeffect is worth pursuing because of the
potential benefits for disease prevention.
Biological Markers
of Susceptibility
Definition ofSusceptibilityMarkers
A biomarker ofsusceptibility is defined as
an indicator or a measure ofan inherent or
acquired ability ofan organism to respond to
the challenge ofexposure to a specific xeno-
biotic substance (1). Biomarkers ofsuscepti-
bility are concerned with factors in kinetics
and dynamics ofuptake and metabolism of
exogenous chemicals. Thus the concept
encompasses enzymes of activation and
detoxication, repair enzymes, and changes in
target molecules for toxic chemicals. Many
ofthe latter conditions include factors that
confer highly increased risks to predisposed
individuals (i.e., repair gene defects, "frag-
ile" DNA conditions, etc.). Susceptibility
factors occur along a continuum from
"near-obligatory" determinants ofhigh risk
to contributory low risk factors (such as
metabolic polymorphisms). In this docu-
ment, we focus on those factors that involve
a major contribution ofgene-environment
interaction to become manifest.
Monogenic traits are inherited in a
Mendelian fashion. A genetic polymor-
phism refers to a monogenic variation that
occurs with at least two phenotypes with
sufficient frequency (> 1%) to cause popu-
lation differences. Genetic variations occur
as either germline inheritance or somatic
cell mutations. Rare inherited metabolic
diseases such as Crigler-Najjar syndrome
occur as a germline mutation (132); a well-
known example ofa somatic cell mutation
is hepatocellular carcinoma caused by
dietary exposure toAFBI (91).
Nongenetic factors such as age and sex
are obviously important but need further
refinement in terms of molecular mecha-
nisms and their interplay with environmen-
tal factors before being useful for any
intervention. Acquired factors (for example
physiological changes, disease-induced
changes, induction and inhibition of
enzymes bydietary factors, etc.) are also crit-
ical but difficult to study because of their
individual nature. Such changes may not be
permanent and thus may be impractical to
take into consideration in any long-term or
retrospective study.
Interindividual variability is observed for
practically all diseases and toxic responses.
It is certainly related in part to different
qualitative and quantitative environmental
exposures, but differences in susceptibility
between individuals in response to the same
level ofexposure are also common. In most
chronic diseases, a long sequence of events
leads to a final response, which is seen as a
result ofan interplay ofmultiple genetic and
other host factors and environmental fac-
tors, each contributing to an overall risk of
having a manifest response.
Although biomarkers of susceptibility
identify those individuals in a population
who have a difference in susceptibility to
the effects of chemical exposure, only in
some circumstances can they predict an
individual's risk with any confidence. It is
important to not generalize inappropriately
from in vitro evidence of susceptibility, as
has occurred in inferring that individuals
with red blood cell glucose 6-phosphate
dehydrogenase deficiency are particularly
sensitive to inhaled ozone (133).
Objectves ofUse
ofSusceptibilityMarkers
Interindividual variation occurs as a result
of different genetically inherited back-
ground modified by dietary and environ-
mental exposure and revealed by genotypic
and phenotypic variation. Susceptibility
markers are useful because they can partially
explain interindividual variation inherent
in the general population and thus provide
a biological rationale for investigation of
inherent vulnerability prior to exposure to
environmental hazards.
The objectives ofthe use ofsusceptibil-
ity markers are the following:
* To evaluate interindividual variation of
risk associated with environmental and
dietary exposure to hazardous chemi-
cals. These methods cannot easily iden-
tify all individuals at risk in a hazardous
environment due to lack ofunderstand-
ing of the interaction of compensatory
genetic and cellular mechanisms and
complex environmental influences.
While individual susceptibility may only
occasionally be specifically linked to a
single defective gene (e.g., CYP2D6)
where the specificity ofsubstrate struc-
ture has been better characterized, it
currently is our best approach to assess
populations at risk.
* To determine the role ofgenetic varia-
tions to explain interethnic differences
associated with susceptibility to chemi-
cal exposures and to predict population
vulnerability.
* To improve the detection of environ-
mental hazards by increasing the sensi-
tivity ofepidemiological studies which
in turn will result in a) reduction of
risk through avoidance or limitation of
chemical exposure b) changes in dietary
and social habits to improve health or
reduce risk c) improved drug treatment
to maximize response and minimize
toxicity. Better knowledge ofxenobi-
otic metabolism and pharmacokinetics
of elimination of toxins will speed
progress ofthis work.
MethodologyinStudying
Susceptibility-related Genes
The approaches and methods described in
this section will focus on studies ofpoly-
morphisms in xenobiotic-metabolizing
enzymes. However, most ofthese methods,
in particular the molecular techniques, can
be used for studying polymorphisms of
other susceptibility-related genes, such as
DNA repair enzyme genes or disease genes.
In addition to the polymorphisms of
susceptibility-related genes, other genetic
alterations such as "mini- and microsatel-
lites" are also believed to be important in
human carcinogenesis and are involved in
individual susceptibility (134).
There are two important parts in studies
ofgenetic polymorphisms. The first is how
to identify a new polymorphism and its
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possible functional significance. The second
is how to define the role ofa known poly-
morphism in human susceptibility to envi-
ronmental toxicity in which the frequency
distribution ofthe polymorphic genotypes
or phenotypes should be determined. In
both cases the PCR technology has greatly
increased our ability to study genetic poly-
morphisms. In the PCR reaction specific
stretches of the DNA can be amplified
exponentially by thermostable DNA poly-
merases with a pair of specific primers.
Several methods arewidely used in studies of
genetic polymorphisms and interindividual
variations in chemical metabolism.
Methodsfor Studying Phenotypic
Expression. USE OF PROBE DRUGS IN VIVO.
When an appropriate probe drug (with
specificity and safety) is available, meta-
bolic polymorphisms can be identified by
determining the metabolic ratio, i.e., the
ratio ofthe blood or urinary concentration
of the parent drug over its metabolite in
different individuals administered the
probe drug. Metabolic polymorphism is
usually indicated in a population ifthe fre-
quency distribution of the metabolic ratio
is shown to be bimodal or trimodal. For
example, a bimodal distribution ofdebriso-
quine 4-hydroxylation (catalyzed by
CYP2D6) is observed due to the existence
of "poor" and "extensive" metabolizers
(135,136). The role of gender-based
CYP1A2 variability in susceptibility to
bladder cancer has been explored using the
caffeine breath test (137).
USE OF PROBE DRUGS IN VITRO. The
probe drugs can be used for in vitro metab-
olism studies to look for possible polymor-
phisms ofthe metabolizing enzymes, which
are usually indicated iflarge interindividual
variations in the activities are observed.
Diagnostic probe drugs for individual CYP
enzymes have been developed such as
coumarin for CYP2A6 and caffeine for
CYP1A2 (138).
OTHER METHODS. Polymorphisms of
xenobiotic-metabolizing enzymes can be
determined at other phenotypic levels.
Enzyme protein levels can be measured by
immunological methods such as immuno-
blotting and immunohistochemical analy-
ses. mRNA levels are quantified bydifferent
nucleic acid hybridization techniques
(Northern and slot blotting, RNase protec-
tion, and in situ hybridization). Quanti-
tative RT-PCR (reverse transcription ofthe
mRNA to cDNA followed by PCR ampli-
fication) has been developed for detection
of mRNA in a small amount of tissue
samples. Expression of CYPIAI mRNA in
human lymphocytes and its regulation
by tetrachloro-dibenzo-p-dioxin (TCDD)
have been successfully determined by this
method (139).
Most genotoxic chemicals need to be
metabolically activated to exert their effects.
Therefore variations in the activities ofthe
xenobiotic metabolizing enzymes by poly-
morphic changes can influence the geno-
toxic effects. Biomarkers ofeffect, such as
cytogenetic damage caused by a genotoxic
compound, can be used as an indirect mea-
surement to evaluate the metabolic activity
of cells from donors with different poly-
morphic genotypes or phenotypes. The
commonly used cytogenetic parameters
include CAs, SCEs, and MN (46).
Methods for Studying Genetic
Polymorphisms. IDENTIFICATION OF
NOVEL GENETIC POLYMORPHISMS. Once a
metabolic polymorphism (or a polymor-
phism at other phenotypic expression lev-
els) is demonstrated, various molecular
biology techniques including cloning and
DNA sequencing can be used to look for
possible genetic changes ofthe enzyme. A
successful example is the discovery of
CYP2D6genetic polymorphism (140).
After cDNA cloning and DNA sequencing,
it was demonstrated that a mutant 2D6
allele is responsible for the majorityof"poor
metabolizers." Further work established that
a mutation at a splicing site caused the pro-
duction ofdefective 2D6 mRNAand a total
absence of2D6 protein (141).
The DNA sequence alterations can be
screened by SSCP analysis, which detects
the mutation-caused mobility shift of the
DNA fragments on gel electrophoresis
(109), or by DGGE, in which DNA mole-
cules are separated based on differences in
their melting temperatures due to the
sequence alterations (113). In some cases,
the variant alleles are detected by sequence
comparison with no knowledge of the
related phenotypic polymorphism. Most of
the polymorphisms will not have a func-
tional significance. Functional analysis is
then critically important in establishing the
phenotypic significance of these variant
alleles. Catalytic activity ofenzymes can be
studied by expressing different variant pro-
teins with the cDNA expression systems if
the polymorphic changes are localized in
the coding region, such as in CYP2A6
polymorphism (142). If the polymorphic
loci are in the noncoding region, their
effects on the transcriptional regulation can
be studied bylinking the mutated sequence
with a reporter gene, such as in CYP2E1
RsaI polymorphism (143).
GENOTYPING OF POPULATIONS. It is
rather simple to determine an individual's
genotype with respect to a specific locus by
current molecular biology techniques,
when the polymorphic sites of a xenobi-
otic-metabolizing enzyme gene are clearly
identified. If a polymorphic site changes
the recognition sequence of a restriction
enzyme, or the polymorphic alteration
involves a large deletion, the genetic poly-
morphism can be identified by RFLP
analysis in which DNA is subjected to
Southern blotting after digestion with
appropriate restriction enzymes and
hybridized with specific probes.
PCR technology has greatly increased
our ability to detect genetic polymor-
phisms. DNA amplification can be carried
out with specific PCR primers for any par-
ticular sequence of a polymorphic gene,
with small amounts ofhuman tissue or cell
samples. The DNA source can be from
blood leukocytes, buccal epithelial cells,
hair roots, and exfoliated cells such as blad-
der epithelial cells in the urine. The PCR-
amplified DNA sequence containing the
polymorphic sites can be analyzed by RFLP
with restriction digestion and visualized on
a stained gel after electrophoresis. If the
genetic polymorphism results in a loss, or in
some cases a gain, ofa restriction site, the
band pattern on the gel will be different
from the wild-type samples, such as in
CYP2E1 polymorphisms (143). Ifthe PCR
primers are designed to be within the miss-
ing sequence ofa deletion polymorphism,
no PCRproductwill be formed.
Obviously, the RFLP method cannot be
used to screen the genetic polymorphisms
in which the sequence alterations cause no
changes at suitable restriction sites. In this
case, genotyping can be carried out by cre-
ating a restriction site by mismatch primers
(144,145) or by allele-specific PCR (146).
If necessary, the results from PCR-RFLP
and allele-specific PCR can be confirmed
byPCR-direct sequencing (147).
Advantages andLimitations
ofGenetcSusceptbilityMarkers
Determinants of the Quality!
Appropriateness ofthe Approaches.
ASSESSMENT OF AN EXPOSURE. The reliable
characterization and assessment ofthe level
ofexposure(s) in the population studied is
an important task. However, there are dif-
ficulties in measuring exposure because
assessment methodologies frequently
depend on personal recall (148,149).
In many studies published so far on meta-
bolic polymorphisms and susceptibility to
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environmentally induced diseases, the
exposure data are either very scarce or not
available. This may contribute in part to
the divergent findings reported for potential
host factors in individual responses to toxi-
cants. Knowledge ofthe substrate specificity
of the polymorphic enzyme studied is
needed before any interpretations concern-
ing its potential effect on individual
response to agiven exposure can be made.
SELECTION OF THE STUDY GROUP. The
cases and controls should have comparable
exposures in studies on individual responses
to environmental agents. Age and gender
matching should also be performed. Ifthese
potential confounding factors are not con-
trolled, the effect may be nullified (150).
Where matching is not possible, logistic
regression can be used to evaluate the indi-
vidual contributions bymultiple factors and
to identifyconfounding factors (151).
SAMPLE COLLECTION. The sample
collection is one important aspect of the
appropriate assays. The proper treatment
and storage ofthe samples is a prerequisite
for obtaining good results. For instance,
blood samples for DNA analyses can be
stored in a refrigerator for several days and
subsequently may be transported on ice or
frozen for transportation or for further
storage. In contrast, the samples collected
for RNA analyses have to be frozen imme-
diately, preferably in liquid nitrogen, and
stored at -800C before use. Blood, which
has been the most used source of DNA
samples, should not be collected in heparin
tubes for DNA extraction. Interference
with the PCR assay occurs when compared
to the DNAextracted from blood collected
in EDTA tubes. Although the DNA-
bound heparin can be removed using
heparinases, they are far too expensive to
be used in studies involving large sample
sizes. The inhibition can be decreased by
extensive dilution ofthe samples (152).
In future studies, increased use ofalter-
native sources ofthe DNA for genotyping
studies, such as cells from buccal mucosa
(153), is expected. These samples are easily
collected by scraping or mouth washing
and will thus overcome some ofthe prob-
lems associated with blood sampling. Aside
from the samples collected for "prospec-
tive" studies, the DNA can also be from
stored pathological tissue sections, which
provide great advantage for retrospective
studies but have additional problems due
to the small amount ofDNA obtained and
due to possible DNAdegradation.
NUMBER OF MARKERS STUDIED SIMULTA-
NEOUSLY. Given the number and variability
in expression ofthe xenobiotic metabolizing
enzymes, assessment ofasingle polymorphic
phenotype or genotype cannot be expected
to be sufficient for evaluating individual sus-
ceptibility to environmental agents. The
ultimate goal should thus be to concurrently
assess individual phenotypes or genotypes
for all the metabolic genes relevant for a
given exposure (154). This may raise an
urgent need for software to aid in the inter-
pretation ofthe overall risk contributed by
several different host factors.
Phenotyping versus Genotyping.
Phenotyping has been widely offered as a
more appropriate method compared to the
new DNA-based techniques in studies on
individual metabolic capacity. Deter-
mination of the actual phenotype of an
individual, although more time consum-
ing, is justified when no genotyping meth-
ods are available or when the correlation
between the genotype and phenotype is
very poor. However, in most cases the cor-
relation is fairly good. Moreover, pheno-
typing is easily affected by confounders
such as food or drug intake prior to testing,
which do not affect genotyping analyses.
Protein and mRNA levels, although
they give some indication ofthe expression
level ofa given metabolic enzyme, do not
necessarily reflect the metabolic activity
(155). On the other hand, the power of
PCR to detect only a few copies ofthe tar-
get sequence makes it particularly vulnera-
ble to errors caused by contaminating
DNA. Both approaches will be discussed in
more detail below.
PHENOTYPING ASSAYS. Use ofprobe
drugs in vivo. The identification ofpoly-
morphic traits has repeatedly been by in
vivo probe and involves the collection of
blood or urine usually over a specific
period. The use of in vivo probes gives a
picture of the whole body capacity for a
specific enzyme to metabolize a given
substance. Probes are not yet available for
all known polymorphically expressed
enzymes. In many cases the probe is
metabolized by other enzymes as well,
which may complicate interpretation. It is
also important to have a probe that is both
specific and safe for use in humans.
Use ofprobe drugs in vitro. Because of
drug/chemical toxicity, the use of an
in vitro probe may be the only safe alterna-
tive to perform phenotyping. A simple
in vitro assay can be developed, ifthe poly-
morphic enzyme is expressed in blood
cells. The use ofother tissues, such as liver
biopsies, may provide an opportunity to
measure the expression level ofthe enzyme
as well. Concerns for patient safety limit
the availability ofthese tissues for study.
GENOTYPING ASSAYS. DGGEandSSCP.
DGGE and SSCP methods are widely used
for detection ofalterations in oncogenes
and tumor suppressor genes, but they could
also be used to track down sequence varia-
tions in the genes coding for xenobiotic-
metabolizing enzymes. Recently they have
also been used as a genotyping methodol-
ogy (156), but at present the RFLP- and
PCR-based analyses may be more useful in
these studies.
RFLP assays. The early RFLP-based
genotyping studies by Southern blotting
were time consuming and labor intensive
and usually incorporated the less desirable
use ofradioactive probes. Southern blotting
has been mainly replaced by PCR-based
analyses, which have greatly facilitated
studies ofindividual susceptibility. This is
best exemplified by the rapid expansion of
the studies on GSTM1 polymorphism after
elucidation ofPCR-based methods (157)
for detection ofthe gene deficiency (158).
Although several PCR-based methods are
available for detection ofhomozygous gene
deletions (157,159), amplifications (160)
or heterozygous deletions (158) of the
genes are still detectable only by the
Southern blottinganalyses.
PCR-based methods. As mentioned
above, the PCR methods have mainly
replaced the genomic DNA methods in
genotyping studies. The RT-PCR is also
used to quantitate tissue-specific expression
of the metabolic genes (161). While rare
mRNA transcripts can be detected by the
RT-PCR approach, determination ofrela-
tive or absolute copy number may be more
problematic (162). Consequently, there is
debate about whether RT-PCR is suitable
for these studies.
One advantage ofPCR methods is the
requirement ofonly nanogram quantities of
the DNA or RNA template. The need for
starting material can be further diminished
by employing a multiplex PCR that gives
the genotype of several metabolic genes
from the same sample. However, optimiza-
tion of the multiplex PCRs may be time
consuming and the number ofassays one
can add to one reaction is relativelylimited.
The evident disadvantage in PCR
methods is their extreme sensitivity to con-
taminating DNA. Consequently, special
emphasis has to be put on controlling the
contamination (163). This can be achieved
by minimizing the possibilities for con-
tamination to occur, by UV radiating the
reaction mixture before adding template
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DNA, and by using carefully selected posi-
tive and negative internal controls in all
amplifications. An additional limitation,
specific for RT-PCR, is that measurement
ofmRNA levels does not necessarily reflect
metabolic activity.
Sequencing. Sequencing is the only
method that provides the actual DNA
sequence of interest. Consequently, it is
still used mainly to identify novel allelic
variants and to confirm the applicability of
new genotyping methods. As the method-
ology improves, sequencing may be more
commonly used to determine genetic
markers (164).
Ethical considerations. Ethical review of
all studies regarding human risk is appropri-
ate. Specific issues arise with the use of
archival samples forwhich donorpermission
may not have been obtained for the current
research investigation. Current practice is
variable regarding the need for consent. A
second issue is the type and quantity of
information derived from the project that
should be provided to the subject [see below
and Soskolne (15)].
Condusions andRecommendations
There are a large number of different
methods to measure susceptibility factors,
ranging from the activity ofan enzyme to
the detection of mutant alleles of a gene
associated with a modified phenotypic
trait. In an era of molecular biology,
exceedingly sensitive and specific methods
to detect alleles and expression ofgenes of
interest have taken center stage; but one
has to keep in mind that it is actually the
phenotype that is of importance for the
final response to the hazardous insult.
One serious problem in phenotyping
studies is lack ofknowledge ofthe levels of
enzymes in the target cells and organs rele-
vant to the whole body metabolism and
the correlation of genotype with in vivo
phenotype. In humans, practical considera-
tions dictate to a large extent that one has
to resort to surrogate tissues.
Genotyping has some advantages, such
as unequivocal identification and lack of
interference with confounding factors; but
a modified sequence within a gene (poly-
morphism) must be demonstrated to
generate a different phenotype.
In vivo phenotyping has the advantage
in some cases ofassigning a value with one
assay that might require determination of
multiple genotyping assays when several
alleles are present in the population. In vivo
methods to measure phenotype may lead to
misclassification of different genotypes,
which in the case ofrare alleles can have a
large effect on the frequency.
To fully exploit the genetics ofxeno-
biotic metabolizing enzymes as risk assess-
ment tools, much more information on the
structure/function relationships and regula-
tion of these enzymes correlated to the
in vivophenotype mustbe elucidated.
On the basis ofthe current knowledge
ofthe field and ofthe above conclusions,
the following recommendations are made:
a) Phenotyping should be continued
along with genotyping, until we gain expe-
rience with large numbers to enable inter-
pretation ofmore complex relationships.
b) The combined impact ofall relevant
genes for agiven exposure (as far as theyare
known) needs to be assessed through popu-
lation-based studies using multiple markers.
New insights into the physiologic function
ofgenes encoding xenobiotic metabolizing
enzymes will be revealed by studies of
transgenic "knockout" or"insert" models.
c) Better kinetic characterization of
enzyme substrate and inhibitor specificity
must be determined through studies of
human tissues, as well as through detailed
metabolic studies ofwhole organisms. The
future availability ofcrystal structure of
drug metabolizing enzymes in combination
with computational chemistry will provide
better information on structure/function
predictions.
d) A greater understanding ofthe regu-
lation of enzyme expression by environ-
mental agents is needed.
e) The value ofintermediate markers of
exposure such as DNA adducts, should be
studied and related to other end points of
disease, e.g., cancer, by cohort studies of
individuals who have had unintentional
exposure.
f) Widely available software for inter-
pretation ofthe overall risk contributed by
several different host factors is needed.
g) Better methods ofDNA sample col-
lection should be devised to facilitate stor-
age and transport and to reduce costs
because of the need to perform complex
DNAinvestigations at remote laboratories.
h) A future approach will be to use
information obtained from analysis ofpop-
ulations of interethnic groups, in an
attempt to modify risk by reducing expo-
sure to potentially hazardous environmen-
tal and dietary factors linked to disease.
The effects ofthese actions must be evalu-
ated to validate proposed interventions.
i) All of these areas need further
exploration before we will be able to assign
individual specific prevention strategies.
Factors That Determine the
Susceptibility ofOrganisms,
Species, Communities, and
Ecosystems
Introduction
There are both commonalities and differ-
ences between the sections on human and
nonhuman organisms in this report on sus-
ceptibility. Many ofthe techniques are the
same, but whereas for human health the
main consideration is the protection of sus-
ceptible individuals, in environmental
terms we are more concerned with suscep-
tible species and communities. Even this
concern is double edged, as there are
species for which human efforts to control
have led to the formation ofhighly resis-
tant forms. Studies of the mechanisms
whereby this resistance has occurred have
given much valuable information on
the differences between susceptible and
resistant populations.
While this section of the joint report
follows the sequence of the human health
sections, namely, biomarkers of exposure,
effect, and susceptibility, emphasis is given
to the last category as in general the same
biomarkers of exposure and effect are used
in human and nonhuman biota. Examples
ofhow these biomarkers are used in the
environmental context will be given.
Here we use the term biomarker as a
biological change that is a measure ofexpo-
sure and sometimes oftoxic effect caused
by environmental chemical(s) at the level
ofthe individual or below. Changes occur-
ring above the level of the individual are
referred to as biological indicators.
The discussion here on susceptibility
covers a broad canvas. There is first a dis-
cussion of biomarkers ofsusceptibility at
the cellular and molecular level, followed by
those at the individual level, both long and
short term. Then we move up the organiza-
tional scale discussing biological indicators
ofsensitivity at the population, community
structure, and ecosystem levels. We con-
dude with two case examples ofindividual
chemicals or chemical classes to illustrate
these points. Finally, we note that humans
are part of ecosystems, and the biomarkers
of ecosystem susceptibility can also indicate
and predict effects ofchemicals on humans.
The best biological indicators will both
warn humans ofpotential danger and alert
us to severe ecosystem damage (Figure 2).
Biomas ofExposure andEffect
We regard biomarkers of exposure and
effect as essentially a continuum (Figure 2).
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Figure 2. The role of susceptibility in individuals, biota, populations, and ecosystems.
Whether a biomarker can be used as an
indicator of effect as well as of exposure
often depends on the depth of our knowl-
edge of a particular case. Thus, we have
not made any effort at making this rather
artificial separation.
Biomarkers and higher level biological
indicators are important tools in ecotoxi-
cology. Their application to studies of
chemical effects on nonhuman biota are
well documented. However, as this does
not fall within the bounds of this discus-
sion, the readers' attention is drawn to a
number ofauthoritative texts (165-167).
Among the hierarchy ofbiomarkers and
biological indicators, representing pollu-
tant-induced changes in biota at all levels of
organization (from the molecular to ecosys-
tem), lie the means to identify, classify, and
ultimately quantify, the susceptibility of
individuals and populations to the detri-
mental effects of chemical exposure. At the
levels ofmolecule, organelle, and cell, there
are a number ofchanges we may use in our
studies of susceptibilities. In the case of
DNA adducts, for instance, we can measure
the quantity and rate ofadduct formation
in one individual and compare it to others
in the same population. Interspecies varia-
tions could also be measured. Similarly,
there are a number of important cellular
regulation and defense proteins that may be
quantified for comparative purposes.
Detoxification proteins such as the
mixed-function oxidases (MFO) and the
cytochrome P450 enzymes may be mea-
sured, as well as the multidrug/multixeno-
biotic resistance proteins. The levels of
such molecules in individuals may give
some important clues to the susceptibility
ofan organism to toxic insult.
Efficient DNA repair has been shown to
be an important determinant of chemical
and radiation-mediated damage in cells.
We may therefore consider the cellular lev-
els ofthe various repair enzymes as indices
of overall susceptibility. Other important
molecules are the proteins involved in cell
regulation mechanisms. Proteins such as the
oncoproteins may be useful, along with the
functional analogues of proteins such as
p53, coded by the tumor-suppressing gene.
Other indicators ofsusceptibility at the
subcellular level include changes in
organelle structure and function, chromo-
somal aberrations, and the formation of
micronuclei to genotoxic agents, as well as
the functional integrity of lysosomes.
These cellular/molecular indicators of sus-
ceptibility may be considered in higher ani-
mals and plants to be only components of
the overall picture of organism response.
Thus they may be used in conjunction
with other higher level markers. However,
for a large number of single-celled organ-
isms (and simple organisms) they may play
a more important role.
Chemical-induced changes in many
types ofcells, tissues and organs can also be
seen as markers of susceptibility. A high
level of cellular dysfunction results in dis-
tinct morphological and biochemical conse-
quences. An example is apoptosis or
programmed cell death. The function of a
cell may be so impaired, or damage to its
DNA so great, that a "suicide" sequence is
initiated, resulting in degeneration and
death. Such a process may be measured his-
tologically, and the levels ofapoptosis mea-
sured in a target tissue or organ. Cellular
dysfunction may also be measured in a bio-
chemical manner, and tracing increases
and/or decreases in tissue specific molecules
such as hormones and enzymes may be a
key indicator ofindividual susceptibility.
Finally, physiological parameters are
potentially important markers, as they
relate directly to fitness and consequently
have higher level effects. Also included are
homeostatic processes such as thermo- and
osmoregulation, alteration to respiration,
and changes in cardiac function.
DNAAdducts
32P-posdabeling has been used for a number
ofenvironmental studies. Some ofthe most
detailed are those carried out in Puget
Sound in the State ofWashington. Varanasi
et al. (168) used the 1-butanol adduct
enhancement method to measure the level
ofDNA adducts in English sole (Parophyrs
vetulus) that were exposed to high concen-
trations of sediment-associated chemical
contaminants and exhibited elevated levels
of hepatic neoplasms. The level of DNA
adducts in contaminated sites averaged
from 17 to 26 nmol/mol nucleotides com-
pared to < 0.2 from a control site. The
finding that the levels ofaromatic hydro-
carbons in the sediments of Puget Sound
were positively correlated with prevalence
ofhepatic neoplasms and related lesions in
English sole were compared to those found
for the starry flounder (Platichthys stellatus)
(169). These workers found that the starry
flounder had a lower prevalence ofhepatic
neoplasms and studies suggested that bio-
chemical differences in the metabolism of
carcinogenic PAHs can explain the lower
susceptibility of the flounder to chemical-
induced hepatocarcinogenesis.
The HPLC/fluorescence spectropho-
tometry approach has been used to show
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the presence ofB[a]P adducts in a popula-
tion of beluga whale (Delphinapterus
leucas) in the St. Lawrence River, whereas
no such adducts were found in the brains
of whales from the Arctic population
(170). The finding ofB[a]P adducts in the
brains of belugas in the St. Lawrence can
be correlated to the high incidence of
tumors (cause of death in 18% of the 61
whales post mortemed) in this population.
The formation of DNA adducts has
been considered a key step in the initiation
ofcarcinogenesis. However, the presence of
DNA adducts in aquatic invertebrates that
rarely or never develop neoplasms may
obviously be linked to genotoxic end
points other than tumorigenesis. Based on
good correlations between the induction of
DNA adducts and gene mutations, it was
hypothesized that, in natural species, a
variety ofmanifestations of the mutational
event may actually prove much more bio-
logically and ecologically important than
the induction ofneoplasia (171).
Strand breakage of DNA has also been
used to study the effects ofenvironmental
pollutants. Although strand breakage can
lead to cell death, in many cases it is
repaired before serious damage occurs.
Strand breakage as measured by the alka-
line unwinding assay is one of a suite of
biomarkers used to study the effects ofpol-
lution on the liver DNA ofbluegill sunfish
(Lepomis macrochirus) in rivers ofthe eastern
United States (172). The basic prerequisite
for the successful use of DNA adduct and
DNA strand breakage in environmental
risk assessment studies, however, is the
recognition of the fact that lower inverte-
brates may be incompetent in forming
DNA adducts from some highly prevalent
pollutants such as PAHs (173).
Some indicators of chemical exposure
and effects methods are shown in Table 2.
Biological Indicators ofSusceptibility
attheIndividual Level
The phenomenon ofresistance is a striking
example of differential susceptibility of
organisms to environmental chemicals.
There are a number ofmechanisms whereby
organisms can resist the action of toxic
chemicals. These include decreased uptake,
increased efflux, increased rate of metabo-
lism of the toxicant, sequestration of the
toxin, and increase or repair of target sites
within the cell. In some cases more than
one mechanism is involved and changes
made against one chemical can protect
against another; hence, the phenomenon
ofcross-resistance.
The factors that influence the onset of
resistance fall into three broad categories:
genetic, biological, and operational. In the
first category is the frequency and domi-
nance of the resistant gene. Dominance is
important; ifthe gene is normally recessive
because it has disadvantages, such as lower
reproductive capacity, the greater the
genetic disadvantage, the slower the resis-
tant strain takes over. The shorter the
generation turnover and the greater the
number of offspring per generation, the
more rapidly resistance can occur. For pes-
ticide resistance, the operational factors
include the actual pesticide used and the
mode and area of application. It is in the
area of disease resistance in insects that we
have the greatest control (174).
The degree of resistance can be large.
For example there are houseflies for which
the LD50 for DDT is 3000 times normal,
the main mechanism that defends the
organism being increased levels ofa dehy-
drochlorinase (175). Resistance among
vertebrates is not so evident, although it
has been reported in several species offish,
and the case ofwarfarin resistance in rats is
well known.
Resistance can cause considerable
changes in the community structure of
invertebrates. Man's attempts to control
the pests that affect cotton in northeastern
Mexico and the southern United States is a
good example of the problems that occur
with resistance and the alterations ofcom-
munity structure caused by differential sus-
ceptibility of organisms to environmental
chemicals (176). During the period 1945
to the mid-1950s there was almost com-
plete control of the main pests-the boll
weevil and the cotton fleahopper-by OC
pesticides and there was a spectacular
increase in cotton production. In the mid-
1950s it was necessary to switch to OP
compounds which increased the costs but
cotton was still profitable. Former minor
pests, the bollworm and tobacco budworm
Table 2. Some biomarkers, the pollutant, and their utility for study of environmental susceptibility.
Measure of
Biomarker toxic effect? Pollutant Organization level Reliability index
Inhibition of 6-ALAD Yes Lead Organ, intact animal Sufficiently reliable to replace chemical analysis; can be related
to mechanisms of action
Induction of metallothionein No Cadmium Organ No advantage over chemical analysis; not related to mechanism
of action
Eggshell thinning Yes DDT, DDE, Dicofol Intact animal, population Wide variation in sensitivity; related to reproductive success
Anticoagulant clotting proteins Yes Rodenticides Intact animal, population Has been related to mortality; can be assessed from blood protein
Porphyrin profiles No Several OCs Organ Levels of porphyrins found in samples are well below those causing
adverse effects
Depression of plasma retional Yes 3,4,3', 4'-TCB Tissue, intact animal Dermal and epithelia lesions to specific protein have been shown
and thyroxine
Inhibition of AchE Yes OPs, carbamates Organ, intact animal Easier and more reliable than chemical analysis
Induction of MFOs Yesa OCs, PAHs Organ, population Analysis ofTCDD-EQa has been linked to reproductive success;
P450s related to specific pollutants
DNA and hemoglobin adducts No Largely PAHs Organ Good monitor of exposure, for PAHs, relation to effects
DNA integrity ? Metals, OCs, PAHs Organ DNA damage is serious to the individual but relationship to effects
on reproduction is unknown
Other serum enzymes No Metals, OCs, OPs Organ A considerable number of enzymes altered by pollutants, but
effects are not clear
Immune responses ? Metals, OCs, PAHs Organ Properfunctioning ofthis is critical to health butthere is
considerable reserve
Stress proteins No Metals, OCs Organ Difficult to separate effects from nonchemical stresses
8TCDD-EQ, TCDD equivalents.
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were becoming major pests. By the mid- to
late-1960s all the pests were highly resis-
tant to all insecticides and cotton produc-
tion dropped markedly. The introduction
ofintegrated pest management was needed
to solve this problem.
IndividualSusceptibility. Susceptibility
of individuals to chemical stress, or their
sensitivity to chemicals, is hard to define.
Pragmatically, susceptibility may be defined
as a lack of resistance, or tolerance, to
chemical stress. Such a definition enables
the recognition ofmolecular, biochemical,
or physiological mechanisms that constitute
a biological defense mechanism against
chemical pollution. These include mecha-
nisms dependent upon the activity or levels
ofmixed-function oxidases, N-acetyltrans-
ferases, glutathione S-transferases, glu-
tathione, glucuronidation and sulfation,
heat-shock proteins, and metallothioneins.
The basic characteristic of these biologic
defense/detoxication mechanisms is their
inducibility. The induced state of these
enzymes, often expressed in thousands of
percent increase over natural state, serve as
useful biomarkers ofexposure/effect. Their
activity and inducibility directly influence
the outcome ofexposure to toxic chemicals
(induction of DNA adducts, induction of
single strand breaks in the DNA, induction
ofchromosomal aberrations, modulation of
fitness and the frequency ofdiseases, lethal-
ity, extinction of species). In resistant
organisms both the natural level and more
importantly the inducibility ofone or more
ofthese mechanisms is higher than in sus-
ceptible individuals. Generally, better
response ofdetoxication/defense mecha-
nisms is inversely proportional to suscepti-
bility. Thus, biomarkers ofexposure maybe
used as short-term indicators ofbiological
susceptibility ofindividuals to chemicals:
low response in these biomarkers will
denote a high level ofsusceptibility. For
example, lower inducibility of7-ethoxy-
resorufin O-deethylase activity in carp will
denote their higher susceptibility to toxic
effects ofpollutants.
Using the same pragmatic definition of
susceptibility as a lack of resistance, one
can utilize a recently discovered multixeno-
biotic resistance mechanism (MXR) as a
long-term biomarker of susceptibility of
individuals to chemicals. The MXR repre-
sents a general biologic first-line defense
mechanism, it is taxonomicallybroadly dis-
tributed, and its expression is species
dependent. However, there are considerable
variations in its expression on an interindi-
vidual basis (177). The low expression of
activity of P-glycoprotein, a dominant fea-
ture in the MXR mechanism (178), in, for
example, the snail Monodonta turbinata
specimens living in a pristine marine envi-
ronment, indicates high susceptibility for
accumulation ofxenobiotics and, conse-
quently, higher likelihood ofeffects (179).
In contrast, specimens ofsnails living at
polluted sites, expressing higher activity of
P-glycoprotein due to its induction, are less
susceptible to toxic effects ofxenobiotics
due to a lower level of its accumulation.
Thus, the level ofexpression ofMXR may
be a good long-term indicator ofsuscepti-
bility to chemicals. Similarly, species with
high levels of MXR (P-glycoprotein)
expression, such as mussels (Mytilusgallo-
provincialis, Mytilus edulis, Crasosteragigas)
(180), clam (Corbiculafluminea) (181),
marine snail (M. turbinata) (179), marine
worm (Urechis caupo) (182), or four
marine sponges (183), in contrast to a fresh
water mussel (Anodonta cygnea) and a fresh
water snail (Paludina vivipara) (179), are
not susceptible to chemical pollution.
Thus, the low, or nihil, expression ofMXR
in A. cygnea and P. vivipara are biomarkers
oftheirlong-term susceptibility.
Excellent methods are available
for measurement of a functional state of
MXR (184), as well as for measurement
of concentration of inhibitors of MXR,
the chemosensitizers, in environmental
samples (185).
Several species or groups can be good
indicator species. Very good bioindicators
are the water insects, especially species
and groups of species of the order
Ephemerophera. Ecological niches and
needs oftheir larvae are well known. By
feeding on detritus they accumulate in
their bodies xenobiotics that can be reliably
identified (186).
BehavioralMechanisms. Individuals
can clearly be exposed to chemicals in
situations in which they cannot escape or
move away from the exposure: then they
must rely on biochemical detoxifying
methods to avoid effects. Sessile organisms
that make up most species in the aquatic
world are unable to move away from expo-
sure. However, many organisms, parti-
cularly vertebrates, have a number of
behavioral and life-history strategies that
enable them to avoid exposure to chemi-
cals. These mechanisms make them less
vulnerable or less susceptible to the effects
ofthese chemicals.
The most obvious mechanism to avoid
chemicals is to move away from exposure;
and many animals do this by simplyflying,
swimming, or walking away. This mecha-
nism functions in many species when they
are exposed to high doses ofchemicals such
as occurs during an oil spill. Birds, many
marine mammals, and fish will swim or fly
from advancing oil when it is possible to
do so (187). However, other fish and some
marine mammals will not do so until it is
too late to avoid exposure. Most exposures
to chemicals, however, occur at such
low doses that animals do not, or cannot
avoid them.
The impairment of locomotion or
abnormal behavior ofanimals is being used
to monitor pollutants. Fish have been used
commonly--monitoring the frequency of
coughing (188,189), loss of rheotaxis, or
disturbance ofschooling. These methods
are linked with automatic water sampling
systems to serve pollutant analysis. Direct
measurement ofrespiration through blood
vessels in fish was devised to monitor cont-
aminants (190). Monitoring of mussels'
activity is also practical since mussels
respond to hazardous chemicals by closing
their bulbs. Abnormal web spinning by
caddisfly larvae or failure to make nests by
other aquatic insects are also useful meth-
ods to monitor pollutants. Feeding activity
can be another biomarker. A short-cut
test with Daphnia using toxicant-induced
inhibition offeeding is beingstudied.
For showing the changes caused by
long-term exposure, it is most important to
observe changes in the populations ofindi-
vidual species. Changes in populations that
are useful include the changes in popula-
tion dynamics, fertility and fecundity,
physiological resistance to external factors,
behavior, levels ofparasitism or pathogen
infestation, and changes in the structure of
communities ofsocial insects (186).
Life History Parameters. In addition
to behavior, some life history strategies
allow animals to avoid exposure, thus ren-
dering them less susceptible to exposure
and subsequent effects. Many species
migrate during part ofthe year, removing
them from low-level chronic exposure;
other species hibernate beneath the ground
where they also reduce exposure and thus
theirvulnerability.
The two life history strategies that ren-
der animals most susceptible to the effects
ofchemicals are a sessile life style and a
long life span. Species that are relatively
long lived, such as most vertebrates and
trees, are more susceptible to chronic expo-
sure to chemicals than those that have a
short life span. This factor functions with
chronic, low-level exposure rather than
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acute, toxic levels ofchemicals. Species that
have a life history strategy that involves
short life spans have a reduced susceptibil-
ity to chemicals because the potential for
bioaccumulation is less and their reproduc-
tive potential is higher. Chemicals such as
dioxins, PCBs, DDTs, and mercury, which
bioaccumulate in internal tissues and are
thus available for remobilization into the
bloodstream, can have severe effects on
organisms that live a long time.
Of the invertebrate bioindicators,
insects are the most valuable because of
their quantities and diversity, and because
ofour sufficient knowledge oftheir taxon-
omy, morphology, physiology, and onto-
geny. Their living areas may be rather
limited, their life cycles short, and their
reproductive potential enormous, with
great variations that can be regulating.
These properties are useful for bioindica-
tion. The diversity ofinsect communities is
distinct and cumulation of substances is
specific; it is not difficult to observe
changes in population dynamics and in
individual development because the life
cycles are short. The reproductive system
of insects is very sensitive to biologically
active substances (proliferation offollicular
cells, change in structure and function of
nutritive cells, etc.) This provides the
opportunity to use the reproductive system
ofinsects as a model for testing the effects
oftoxic substances in the environment.
Taxa Variation. In the environmental
field we have to look not only at suscepti-
ble populations ofany one species but also
at interspecies variations that can cause a
differential effect. In this section we exam-
ine a number of biomarkers that vary
widely in their sensitivity from one group
ofanimals to another.
MIxED-FuNcTIoN OXIDASES. MFOs are
a major component of the defenses of
organisms against toxic chemicals in their
environment. Originally evolved to handle
naturally occurring toxic compounds, they
now play an important role in the detoxi-
fication ofman-made chemicals. Nebert
et al. (191) consider that the ancestral
cytochrome gene is probably two thousand
million years old. The major divergence
occurred eight hundred to one thousand
million years ago when animals began
using plants as food and self-defense mech-
anisms against toxins in plants evolved.
Later, additional families ofcytochromes
evolved in response to the necessity to
metabolize combustion products.
There is some variation between taxa:
in general terms, the relative activity ofthe
MFO enzyme epoxide hydrase follows
phylogenetic lines with mammals > birds
and amphibia > fish, with little overlap
between the groupings. Levels in inverte-
brates are much lower. Glucuronyl-
transferase activities were much higher in
mammals than fish with virtually no over-
lap. Aldrin epoxidase activity follows the
same trend, but in this case there is consid-
erable overlap. A linear log relationship was
found between relative activity and body
weight for mammals, with man being the
outlier having activity lower than would be
expected by bodyweight.
Fish-eating birds show a high correla-
tion coefficient for the regression ofactivity
against body weight, with the values for
relative activity being approximately an
order ofmagnitude lower than for mam-
mals ofcomparable weight. Other species
ofbirds tend to have values intermediate
between fish-eating birds and mammals,
but the correlation of activity with body
weight is considerably weaker. Low values
for fish-eating birds are considered to be
due to the fact that until xenobiotics conta-
minated aquatic food chains, the birds had
less need of these defense mechanisms.
Regrettably no data appear to be available
on fish-eating mammals.
The low level of activity in fish has
been considered to be due to the fact that
until historical times this group oforgan-
isms has found the excretory route across
the gills effective for removing most xeno-
biotics. It is clear that this mechanism is
quite inadequate to deal with highly
liposoluble organochlorine molecules that
have been released into the environment by
humans in the last few decades.
The relationship between feeding
habits and MFO activity has also been
demonstrated in insects. A detailed review
of the data for aldrin epoxidase has been
made by Brattsten (192). He found that
aldrin epoxidase activity is lowest in
monophagous species, considerably higher
in oligophagous, and some 10-fold higher
in the most polyphagous species.
The comparison of Phase I and Phase
II hepatic transformation in quail and
trout to that of a number ofmammalian
species commonly used in toxicity testing
has been made by Gregus et al. (193).
They found that the overall metabolism of
xenobiotics could vary several hundredfold
between species.
ToxicrrY OF DIOXINS. The toxicity of
dioxins to various mammalian species
varies greatly. The most sensitive species
known is the guinea pig; the LD50 for the
male is 0.6 pg/kg and the female 2.1 pg/kg,
the value for the male rat is 22 pg/kg, for
the female rat 45 pg/kg and for the rabbit
(mixed sex) 115 pg/kg, whereas the least
sensitive species is the hamster (1200
pg/kg) (194).
EGGSHELL THINNING. The phenomenon
ofeggshell thinning, although confined to
only one order (Aves) does illustrate some
interesting points in susceptibility. Eggshell
thinning is caused by DDE and the sensi-
tivity varies greatly. A diet of only a few
parts per million will cause 20% thinning
(the degree ofthinning that causes eggshell
breakage and thus reproductive failure) in
raptorial birds and some species offish-eat-
ing birds such as the pelican and cor-
morant. Other species such as gull, terns,
and ducks are only moderately sensitive
with diets of40 to 50 ppm being needed
to cause biologically significant eggshell
thinning. Still other species, such as quail
and chicken are completely insensitive and
it is impossible to achieve more than a few
percent thinning even at the highest dosage
that can be used without mortality. One
important point from this variation is that
the common test species are insensitive and
thus even if the measurement ofeggshell
thinning had been included in test proto-
cols for new pesticides this phenomenon
would not then have been recognized.
Another point is that the species exposed to
the greatest amount ofDDE, due to bioac-
cumulation, are those that are the most
sensitive. DDE-induced eggshell thinning
caused the decline ofmany species ofrap-
torial birds, such as the peregrine falcon
(Falcoperegrinus) and european sparrow
hawk (Accipter nisus) overwide areas ofthe
northern hemisphere. These declines have
been reversed in areas where bans on DDT
have been imposed.
Biological Indicators ofSusceptibility
to Chemicals atthePopulationLevel
Biological indicators for assessing sus-
ceptibility at the population level measure
parameters that are a consequence oflow
activity of mechanisms of resistance
detected by molecular and physiological
biomarkers. For example, the induction of
DNA adducts and DNA strand breakages
found in individuals by molecular biomark-
ers predicted the increase in mutational
events in population. Consequently there is
a higher susceptibility ofpopulations to
diseases, especiallyviral, bacterial, and para-
sitic, as the consequence ofimpairments in
the immunosystem. These populations also
are more highly susceptible to decreased
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fitness of population, to impairments in
reproduction, to sickness and increased
lethality. All these indicators ofsusceptibil-
ity of populations to chemical stress will
predict the expected consequences on the
level ofpopulation such as alterations in
adaption, survival and succession. On the
ecological level, the most severe effect-
extinction ofa species-can occur.
Several examples illustrate the use of
implications ofsusceptibility at the popula-
tion level. In salt marsh ecosystems of
North America, salt marsh grass (Spartina
alterniflora) is the primary producer; sus-
ceptibility ofthis species to specific chemi-
cals, which results in lowered reproductive
output, would have a greater effect on
community and ecosystem structure than
would susceptibility ofother, less impor-
tant plant species (195). S. alterniflora is
susceptible to PAHs from oil pollution; the
sensitive vegetative propagules can be killed
and the species may take years to recover.
Similarly, differences in susceptibility to
chemicals among species of algae in salt
marsh communities would also have a crit-
ical effect on community and ecosystem
structure since algae productivity is critical
to the overall productivity of the animal
communities in the marsh.
Equally important to remember when
using cellular and molecular biomarkers as
measures ofthe susceptibility ofcommuni-
ties and ecosystems to chemicals, is that
changes in molecular and cellular organiza-
tion must have effects at the population
level to be important for community and
ecosystem structure.
In many cases, chemical, physical, and
biological stressors occur together; and the
communities and ecosystems must contend
with them at once. Since communities and
ecosystems are assemblages oforganisms,
and thereby are populations that make up
the system and are responsible for the stabil-
ity and repair of that system, the relative
susceptibility ofthat system depends on the
susceptibility ofindividuals and populations
within the system.
Biological Indicators ofSusceptibility
to Chemicals attheCommunity Ll
Within any community or ecosystem the
species are not necessarily ofequal impor-
tance with respect to the maintenance of
stability. That is, some species have a key-
stone role (196). Keystone species include
species that provide key nutrients or energy
at the lower trophic levels, or species that
regulate competition and predation at the
higher trophic levels. Where molecular and
cellula'r biomarkers are used to indicate
potential susceptibility differences among
individuals or species, care must be given
to select indicator species that have a key or
pivotal role in community structure (197).
Chemical disruptions to species that are
essential for either the structure or the
function ofthe system will have a greater
effect on the susceptibility ofthe ecosystem
than those that are less critical.
Several measures of the structure and
function of communities and ecosystems
(Table 3) can be used to measure change
(167,197-201). The degree ofchange in
ecosystem structure and function that
occurs is a measure ofsusceptibility. That
is, ifa community or ecosystem undergoes
few changes in either structure or function
in response to a chemical, biological, or
physical perturbation, then it is relatively
resistant or can be said to be less suscepti-
ble to the effects of a given chemical or
class ofchemicals.
The methods to evaluate community
and ecosystem change are often costly and
time consuming, but they can sometimes
be used with less technology and equip-
ment. That is, in places or situations where
extensive molecular and cellular laboratory
facilities are not available, the community
and ecosystem measures outlined in Table 3
Table 3. Methods to measure differences in suscepti-
bility atthecommunity and ecosystem level.a
Usefulness
Ease of measurementa for chemical
Characteristic Aquatic Terrestrial assessmentb
Biodiversity 1 5 A
Relative density 1 2 A
Relative abundance 1 1 A
Dominance 5 5 C
Foodweb 8 8 A
characteristics
Genetic diversity 10 10 A
Primary productivity 1 1 A
Secondary 5 3-7 B
productivity
Decomposition 1 1 A
Energyflow 5 3 C
Mineral cycles 8 3 A
Nutrient cycles 8 5 B
Keystone species 5 5 A
Indexofbiotic 10 10 A
integrity
Guild structure 10 8 C
Biomass 10 10 A
Erosion 5 5 C
Revised from Burger and Peakall (195); and several
articles in this volume. Ease of measurement is
scored on a continuum of 1 to 10, 1 being the easiest
to measure, 10 the most difficult. bUsefulness for
assessment is scored on a continuum, A being most
useful, Cthe least useful or indicative.
can be effectively used to determine differ-
ences in susceptibility. On the other hand,
where such laboratory facilities exist, some
ofthese techniques can be used effectively
as surrogates to determine whether individ-
ual reproductive potential is compromised,
thereby affecting population levels, and by
extension, community structure. Table 3
also gives an indication ofthe difficulties of
each methodology, as well as its usefulness
for evaluation ofthe effects ofchemicals.
One ofthe most detailed studies at the
community structure level was made in
Canada to determine the effects caused by
acidification in an experimental lake situa-
tion (202). In this study the pH ofa poorly
buffered lake in northwestern Ontario was
reduced from pH 6.8 to pH 5.0 over 8
years. Fish populations started to collapse
due to lack ofreproduction when the pH
reached 5.9, and there were marked changes
in the phytoplankton composition although
primary production was not decreased. At
pH 5.6 thick mats of filamentous algae
appeared, which persisted throughout the
study. When the stable value ofpH 5.0 was
reached the species composition ofphyto-
plankton was completely different although
primary production remained high; no fish
reproduction was occurring; crayfish,
leeches, and mayflies were absent; but there
was a considerable increase in chlorophyll
and no changes in nutrient concentration
were observed.
Cas Studies
Lead. Lead is an exampleofhowbiomarkers
can be used at different levels oforganiza-
tion. Concentrations oflead in tissues such
as blood, liver, and kidney are measures of
exposure. Analysis of levels of lead and
other heavy metals, however, is costly and
requires technical knowledge and sophisti-
cated equipment. However, 8-aminole-
vulinic acid dehydratase (6-ALAD) activity
can also be measured in blood as a bio-
marker ofexposure and effect (203). It is a
cheaper and easier method ofanalysis than
oflead itself.
Additionally, the effects oflead can be
measured with a number ofneurobehav-
ioral assays, since one ofthe primary non-
lethal effects of lead is on cognitive,
psychomotor, and other neural processes in
both human (204) and nonhuman biota
(205,206). Lead can cause mortality
directly, or can cause lowered reproductive
success through depression ofclutch and
egg size, mortality ofembryos, depression
ofgrowth, and disruption ofreproductive
behavior in a variety ofspecies, especially
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on birds, the work on which has been key
(206). There are differences in susceptibil-
ity among birds: seabirds such as gulls and
terns are more susceptible than chickens,
ducks, and passerines (207-209).
Lead shows the classic trophic level
relationships with respect to vulnerability:
species that are higher on the food chain
have higher levels ofexposure than those
that are lower on the food chain (206).
However, susceptibility will also vary with
such factors as developmental maturity at
hatching, at least in birds. That is, lead dis-
rupts parental recognition, making those
species dependent on recognition (i.e., pre-
cocial birds) more susceptible to the effects
oflead than species that do not depend on
this recognition (210). Humans are at a
relatively high trophic level and clearly
show effects of lead. These effects, espe-
cially the neurological and behavioral ones,
are particularly apparent during develop-
ment, and persist for many years in
humans (204).
Lead can also have disruptive effects at
the population and community levels. The
abnormalities caused by lead can reduce
survival and lower reproduction success,
resulting in lowered population levels for
impacted populations (206). The effects in
humans have the potential to severely alter
social structure and behavior of popula-
tions that are severely exposed (204). As
early as the 1950s, Bellrose demonstrated
that lead poisoning could depress popula-
tion levels by differentially affecting those
wounded by hunters, and the response was
dose related (211). Similarly, birds nesting
along roadways are heavily exposed to lead
from gasoline, while those in more remote
areas are not. Animals near smelters are
also heavily exposed through the aquatic
food chain. By differentially affecting dif-
ferent species, the species composition of
communities can be affected by lead, lead-
ing ultimately to changes in ecosystem
structure. Because organisms higher on the
food chain are more susceptible, this end of
the system would be more affected.
While the mechanisms whereby lead
affects hemoglobin formation (e.g., inhi-
bition of 8-ALAD) are well known, the
mechanisms disrupting neural systems,
development, and behavior are not well
established. These phenomena have been
quantified, without clarifying the mecha-
nisms. Phenomena include differences in
cell growth and neuronal projections.
PCBs andDioxins. The mechanism of
action ofPCBs, polychlorinated dibenzo-
furans (PCDFs), and polychlorinated
dibenozo-p-dioxin (PCDDs) is considered
to proceed via initial binding to a high
affinity, low capacity cytosolic receptor
protein. The identification ofthe Ah recep-
tor (212) with stereospecific, high affinity
binding to 2,3,7,8-TCDD was a key find-
ing in bringing molecular biology into the
realm oftoxicology. Examining the toxico-
logical and receptor binding data, Poland
and Knutson (213) concluded that it was
likely that these compounds exert their
toxicity through the cytosol receptor.
The ability of specific PCBs, PCDFs,
and PCDDs to induce the P4501 system is
greatly influenced by the degree ofchlori-
nation and the chlorine substitution pat-
tern. The most toxic PCBs are those that
are unsubstituted in the ortho positions,
i.e., 3,3',4,4'- tetrachlorobiphenyl (TCB),
3,3',4,4',5-pentachlorobiphenyl, and
3,3',4,4',5,5'-hexachlorobiphenyl, which
allows the molecule to assume a co-planar
configuration. There is a close relationship
between aryl hydrocarbon hydroxylase
(AHH) induction and body weight loss,
and AHH induction and thymic atrophy,
although the interactions ofenzyme induc-
tion, receptor binding, and toxicological
manifestations are very complex and our
knowledge is far from complete.
Problems that have to be faced before
one can use this approach for wildlife toxi-
cological investigations in the field are
extrapolations from species to species and
extrapolations from cell culture to the
intact animal. Brunstrom and co-workers
have carried out studies on avian embryos.
Marked differences were found in the sen-
sitivity of the chicken, pheasant, turkey,
duck, and gull (214-216). They found
that the pheasant was 50 times less sensi-
tive than the chicken, and other species
were even less sensitive. This emphasizes
the difficulties of interspecies comparison
since the chicken and pheasant both
belong to the order Phasianidae.
The application of this complex
biochemistry to field investigations has
been based on expressing the complex mix-
tures of PCBs, PCDFs, and PCDDs as
dioxin equivalents (TCDD-EQ). Based on
their affinity for the Ah receptor, the activ-
ity ofthe individual congeners are assigned
a value relative to the most active com-
pound (2,3,7,8-TCDD) which is given a
value of 1. These toxic equivalent factors
are multiplied by their concentration to
give TCDD-EQ for each compound.
Although even the co-planar PCBs are a
good deal less active than 2,3,7,8-TCDD,
their concentrations are much higher and
thus they contribute more than the dioxins
to the total TCDD-EQs. Now it is possi-
ble to do the process in reverse and use
the degree ofenzyme induction to estimate
the TCDD-EQs. This bioassay approach
is rapid and inexpensive compared to
the conventional chemical analysis by gas
chromatography-mass spectrometry.
Good correlations have been found
between TCDD- EQ ofegg contents and
both the reproductive success and inci-
dence ofdeformities in fish-eating birds in
the Great Lakes of North America. In
terms of sensitivity, it is of note that the
cormorant is some 20 times more sensitive
than the Caspian tern (Hydroprogne caspia).
In the most contaminated areas of the
Great Lakes, the productivity success has
been linked to population declines.
EthicalIssues andEcosystem
Susceptibiity
There are at least three areas where ethical
considerations impact methods evaluation
for ecological systems: scientist versus all
other stakeholder views, government
actions and ecosystem vulnerability, and,
the conflict between using biomarkers in
ecosystems for understanding the ecosys-
tem itselfand using ecosystems as indica-
tors for human health [see section on ethics
below, and Soskolne (15)]. Increasingly,
the responsibilities of scientists toward
stakeholders (including scientists) are
obscure with respect to how well the
methodologies actually measure the phe-
nomena in question. It is unclear, there-
fore, how soon scientific "findings" should
be released or made available, how strin-
gent the criteria for acceptance ofan effect
must be (given the accuracy ofthe meth-
ods), and how to resolve conflicts between
scientific viewpoints that develop as a result
ofmethodology differences.
Certain communities and ecosystems
are more susceptible to damage from expo-
sure to chemicals by virtue oftheir species
diversities, unique species assemblages, or
presence of endangered species. In these
cases, ecologists and ecotoxicologists have a
responsibility to make the susceptibility
known, and where possible, to affect deci-
sions to reduce the potential for exposure
to chemicals.
For example, the National Research
Council examined the susceptibilities of
offshore communities in the United States
to oil pollution. They determined that the
coast of Florida was very vulnerable
because ofthe presence ofsubtropical coral
reefs and manatees (both limited in the
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continental United States). As a result,
the U.S. government decided not to allow
offshore oil exploration in Florida.
There is a conflict between the use of
biomarkers as indicators ofecosystem health
for itself, compared to using these biomark-
ers only as indicators ofhuman exposure.
We would argue that both are important
uses ofbiomarkers, and biomarkers should
be developed that fit and evaluate the effects
ofchemicals in both. We have an ethical
responsibility to preserve ecosystem integrity
on aworldwide basis.
CondusionsandRecommendations
The following steps should be undertaken
to protect organisms, species, communities,
and ecosystems:
a) development of biomarkers at the
cellular and molecular level that cross-cut
taxonomic levels, including the vastdiversity
ofinvertebrates
b) study ofmolecules and mechanisms
conserved across the animal kingdom;
these highly conserved mechanisms may
also have implications for higher animals
including humans
c) development ofbiomarkers that inte-
grate across all levels ofbiological organiza-
tion because some chemicals may have a
greater effect at lower trophic levels while
others will be more apparent athigherlevels
d) development ofbiological indicators
that identify ecosystems susceptible to
chemicals
e) Development ofbiomarkers that are
rapid and inexpensive and thus capable of
beingwidely used.
Ethical, Social, and
Legal Issues Surrounding
Studies ofSusceptibility
Intoducdon: Ethics as aMethodology
GrowingAttention to Ethics. Since the
early 1980s, there has been a growing wave
of concern about the ethics ofstudies on
biomarkers ofsusceptibility (217-227).
Technological advances continue to chal-
lenge our sense ofwhat may be deemed
"right" and "wrong" or "morally appropri-
ate." These concerns have escalated since
the beginning ofthe 1990s (228-248).
Education in the formal theories, princi-
ples, and rules ofethics generally has not
been an integral part ofgraduate training
among risk scientists. Even though scientists
have tended to focus on "the scientific
method" in their work, there are prominent
examples ofconcern with the ethical dimen-
sions oftheir speciality (249). Notions of
"peer review" are well developed and mech-
anisms for achieving "informed consent" are
firmly in place. However, the social conse-
quences, including both potential benefits
and harms, have been relatively neglected in
manyareas ofscience (250,251).
Utility ofEthies. A briefoverview of
ethical theories in relation to scientific
technologies is provided, with special
attention to their application in the field of
biomarkers of susceptibility. It will be
shown that the discipline ofmoral philoso-
phy, like the scientific specialty areas com-
prising the risk sciences, provides us with
methodologies for analyzing decisions (e.g.,
whether or not to implement a new tech-
nology) and a philosophical basis for our
actions. In practical terms, ethical analysis
provides us with the tools through which
decisions we make can be tested against
ethical theories (and their attendant princi-
ples and rules) as a basis for explaining or
justifying (moral) actions (252).
Ethical Theories and Principles.
Analogous to other disciplines, ethical
analysis has a theoretical basis. Stemming
from each theory are principles and associ-
ated rules, providing a framework for ethi-
cal analysis. Empirical data then are
testable against these theoretical frame-
works. Several theories from the discipline
ofethics warrant review in the context of
biomarkers ofsusceptibility.
Deontology, a duty-based theory that
specifies obligations to be upheld by mem-
bers ofthe profession, is perhaps the most
commonly evidenced ethical theory among
health professionals. The "scientific ethic,"
in fact, is deontological (duty based),
requiring ofscientists, among other things,
to be objective, honest, and unbiased in the
use ofappropriate methods related to their
subspecialty area of practice. Physicians,
too, are bound by duties that derive from
the principles ofautonomy (i.e., the right of
the individual to make independent
choices), beneficence (i.e., the obligation to
do good), nonmaleficence (i.e., the obliga-
tion to do no harm), and distributivejustice
(i.e., social equity). The preeminent duty
among physicians is to not cause harm to
their patients. It is through this duty that
the physicians' role extends to that of
patient advocate. Autonomy, as more
recently interpreted, extends to include
involving the patient as a partner in deci-
sions about care. Distributive justice is
manifest in the principle ofequal access to
care, regardless ofability to pay. These brief
glimpses of ethics relate to physician-
patient relationships (253).
Other relationships among health pro-
fessionals exist. For example, those engaged
in public health have the community's
interests to protect, and usually adhere
more to the utilitarian theory of ethics
requiring that the greatest good be done
for the greatest number of people. This
practice does not predude the indusion in
public health of other principles such as
autonomy, nonmaleficence, and equity.
However, the libertarian ethic has less
utility within public health because it
holds the individual more important than
the community.
The egalitarian ethic holds all commu-
nity members equally important and
upholds the principle ofsolidarity. It mea-
sures the well-being ofthe group by that of
the least well off. As an example ofthe use
ofegalitarianism, the U.S. CleanAirAct sets
regulatorystandards to protect the most sus-
ceptible members ofthe population. The
principle ofjustice that flows from the egali-
tarian theoryprovides forequal access to the
process ofsusceptibility assessment; by the
same principle, the environmental risks
should be fairly distributed across social
classes, ethnic groups, and races. Equal out-
comes cannot be expected because ofthe
nonegalitarian characteristics ofinherited
genetic traits. The egalitarian philosophy,
however, would strive to compensate for
those inequalities through biologically based
treatment orbysocial means.
It becomes evident that, depending on
the ethical theory that one draws upon, one
can rationalize apparently disparate conclu-
sions. This is where normative professional
practices need to be defined as an aid to
individual practitioners faced with dilem-
mas, ethical conflicts, or tensions among
various principles deriving from the respec-
tive theories. The recentlyformulated ethics
ofpostmodernism uphold the principle of
social specificity. This implies that local,
subjective, and sometimes fragmented nar-
ratives may be more appropriate in guiding
the actions ofboth scientists and the com-
munity than traditional overarching or
absolutist theories.
The relational ethic, for those more
familiar with moral philosophy, provides a
basis for making rational comparisons
among the various theories. While it is
often heard that "ethics are value neutral,"
in practice it is generally agreed that ethics
are, in fact, value laden. Hence, relational
ethics can be especiallyhelpful for identify-
ing the theories and principles most appro-
priate to the issues in studies ofbiomarkers
ofsusceptibility.
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Distinguishing between "Research"
and "Practice."A distinction needs to be
drawn between the professional engaged in
research and the professional engaged in
clinical or public health practice. The latter
is often governed by legal requirements
especially in the area ofpublic health prac-
tice where, for example, tensions can arise
between the principle of autonomy (in
terms ofthe right to privacy) and the pub-
lic's right to know about, for example, a
potentially contagious condition that
requires isolation or quarantine.
Research is that area ofprofessional pur-
suit that develops new approaches to pre-
vention, treatment, and cure. Adequate
testing is required to assure that significantly
more good than harm will result before any
new product or technology is made available
for general practice or commercial applica-
tion. Where concern is focused on establish-
ing the sensitivity, specificity, and predictive
value ofa new test, this constitutes research.
Here, access by the individual to his/her
findings in the absence ofany clear inter-
pretation would be inappropriate and vol-
unteers for such research ought to have
been so advised at the time that informed
consent was obtained. Any person, includ-
ing the one who participates in research,
who would wish to know the results ofthe
tests then would be required to await the
conclusion of the scientific investigation
and the availability ofthe test for general
use or practice.
Legal and Regulatory Perspectives.
While new technologies may have appeal as
"magic bullets" to people with concerns for
potential benefit, it is government's role to
protect the public from harmful effects.
Therefore, the involvement ofgovernment
in regulating the use of technologies is
appropriate in those instances where public
exploitation or harm could arise from access
to inadequately tested products, promoted
in the absence ofadequate review. It is the
scientists' role to pronounce the time when
they deem products or technologies to have
been adequately tested and hence safe,
reliable, and accurate enough forpublic use.
There is, however, often a fine line that
separates "safe" from "unsafe." No product
or technology can be said to be absolutely
safe, so regardless ofwhere that cut point is
set, more or fewer untoward (and unin-
tended) effects will be seen. Society has to
be involved in the decisions that define
"acceptable levels ofunintended effects" as a
consequence ofany new technology. It then
becomes the burden ofthose in risk com-
munication to ensure public understanding
ofany risk associatedwith a new technology
used for identifying susceptibilities or for
building risk management policies around
susceptibilityissues.
Ecosystem Perspective. Aside from the
ethical concerns ofprofessionals engaged
directly in human-health-related disci-
plines, indirect concerns that are intricately
tied to the ecosystem also must be consid-
ered. Whether animal species are appropri-
ately used as sentinels (i.e., to serve as
indicator species) for exposure effects on
humans, the ecosphere should be seen as
life sustaining in itself. Hence, damage to
nonhuman species or the ecosphere should
be considered as potentially harmful to
human life. There is also the deontological
ethic that assigns to humans stewardship
responsibility for the natural world.
Therefore, broader concerns than anthro-
pocentric ethics need to be considered in
anyethical analysis.
ContwtofMaco Nature:
Etbica, Soa, Lea
RelationaL The ethical, social, and legal
frameworks ofbiomarker research will dif-
fer depending on the professional and con-
tractual relationships ofthe participants.
Individual relationships, such as between
physician and patient, lawyer and client,
and researcher and participant, are gov-
erned predominantly by a deontological
ethic whereby the providing professional
has the primary obligation to look after
and protect the interest ofthe individual
over all other considerations, including
social benefits. This obligation is recog-
nized in law that protects the privacy and
confidentiality of the physician-patient
and lawyer-client (and, by implication, the
researcher-participant) relationship against
undue intrusion.
This protection may not be complete,
and will vary under different legal, social,
and cultural conditions. For example, the
patient-physician contract may be influ-
enced by the ethics ofthe payor ofservices.
This ethic places constraints on the pri-
macy of the deontologic relationship
because the utilitarian-based principles seek
the use offiscal resources for the maximum
good of the larger population. An addi-
tional threat to confidentiality rests in the
potential vulnerability ofcomputer-based
records in which security may be breached
bytechnological intrusion potentially to the
detriment ofthepatient/client/participant.
The significance ofthese considerations
for studies on biomarkers of exposure,
effects, and susceptibility rests in the
inherent conflicts and tensions that occur
when the payor, courts, employer, or pub-
lic health laws impose requirements on
biomarker data that intrude on the princi-
ples ofprivacy and confidentiality in a way
that is beyond the power of the original
contractees to prevent, and with conse-
quences potentially detrimental to both
parties. In this way, data on genetic suscep-
tibility may be used to exclude workers
from certain job opportunities, or patients
may find themselves unsuspectedly con-
strained bypublic health laws. There is also
the consideration that the worker in pos-
session ofinformation on genetic suscepti-
bility or biologic effect may be motivated,
in the absence ofa full understanding ofthe
limitations ofthe methods, to seek compen-
sation for injury; this could occur in the
absence ofdocumented evidence ofexpo-
sure to a substance in theworkplace because
ofthe lack ofaccompanying technology to
identify exposure.
The prevention and resolution ofthese
difficulties are complex and various
depending on the social, legal, and cultural
environment. The overriding ethical prin-
ciple is, however, that the participants in
these professional/contractual relationships
be made fully aware ofthese possibilities in
agreeing to participate in biomarker
studies, and that the legal frameworks
adjust to the potential negative outcomes if
they stand in the way ofaccomplishing a
desired social goal. The scientist, profes-
sional, ethicist, and lawyer should work in
concert to address these issues, recognizing
the adversarial nature ofthe process and
the desirability ofengaging the professional
organizations in identifying capable experts
to provide testimony.
Sodal Context. Another level ofanaly-
sis needed to broaden an understanding of
ethical concerns on a macro level is the
social context. The implication is that the
technologies used to identify susceptibility
are shaped by a variety ofsocial processes.
On this level ofanalysis, questions sur-
rounding the intended and unintended
social consequences ofdealing with suscep-
tible individuals and populations need to be
raised. For example, will the results ofiden-
tifying relevant biomarkers in an individual,
community, or population have a beneficial
or harmful effect upon current or future
employment; compensation status in terms
ofboth private insurance and public social
security systems; and, more generally, exist-
ing forms ofsocial inequality? In this sense,
ethical discussions must consider that these
consequences may be beneficial as well as
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harmful and this should be recognized
within thescientific community.
Another aspect within the social con-
text that needs consideration is the inter-
face between the public health needs ofa
specific community and the duty ofprofes-
sionals to identify as well as to provide for
some of these needs. Simply, what ethical
demands emerge when professionals are
confronted with susceptibility in a particu-
lar community? This may expose a tension
between utilitarian and deontological theo-
ries. For example, on the one hand a public
health perspective, driven by utilitarian
ethics, upholds the principle ofthe greatest
good for the greatest number. On the other
hand, the deontological ethic, which gov-
erns health professionals, emphasizes their
duty to serve those susceptible in the com-
munity as well as to protect a community's
right to health.
An intervening ethical theory may be
the libertarian theory of rights, which
demands that any health decisions taken,
whether by professionals or the commu-
nity, will be absolutely respectful of indi-
vidual autonomy. Here the emphasis is
that to act ethically, decisionmakers need
to assume that their future actions enable
all persons to attain benefits (on their
own initiative).
It is worthwhile in an ethical context to
consider the impact oflegislative and regu-
latory measures on communities. In light of
the issue ofsusceptibility, what biological
markers appear as important in determin-
ing whether a disease should be reportable
or notifiable or considered communicable?
How does susceptibility status affect regula-
tory measures or official disease classifica-
tions in the field ofpublic health? Answers
to these questions should be informed by
clear ethical principles. But a tension
emerges ifa community's rights for distrib-
utive justice (i.e., social justice or equity)
under the law overrides the social need for
trust in the public health professional.
Still another area ofconcern is the role
of the expert in the formation ofpublic
health policy. Here, a key issue emerges: at
what stage in the production ofknowledge
about susceptibility factors can experts
agree collectively that this knowledge will
contribute to more accurate methods ofpre-
vention? In this way, the ethical principle of
beneficence is upheld. Hence, meeting the
need for sensitivity, specificity, and predic-
tive value in this field has meant that an
effective contribution to prevention should
be able to be recognized. However, other
ethical principles besides beneficence need
to be considered for experts to be successful
in having an impact on the formulation of
appropriate prevention policies.
Most definitely, those involved in
studies on biomarkers ofexposure, effect,
and susceptibility should be cognizant of
the fact that ethics guidelines may vary
across cultures. The sorts ofethical princi-
ples upheld by the scientific community of
a particular culture may differ significandy
from those upheld by their counterparts in
another culture. For example, the basic
tenets ofboth contemporary medical and
public health ethics are derived from major
conceptual developments in Western cul-
tures. Scientists and public health officials
from the "developed world" need to recog-
nize this factwhen theyattempt to compare
studies or assess the utility ofbiomarkers in
the "developing world."
Time-relatedFactors. A third factor in
the context ofthe application ofbiomarker
technology Ls the evolutionary nature of
social, ethical and legal concepts and
norms. The fairly recent institution ofthe
principles and practices ofinformed con-
sent is an example ofevolution in the ethi-
cal conduct ofscience. What is considered
ethically acceptable or legally permissible at
the time an understanding is reached or a
contract negotiated may become ques-
tioned over the life ofthe outcome ofthat
contract, years or decades later, because of
the maturation oflegal, social, or ethical
philosophy. Research studies on captive
populations or using potentially injurious
substances for worthy scientific goals are
no longer considered ethically justifiable or
legally permissible. Indeed, tort action is
proceeding retrospectively.
The status oflegal protection ofconfi-
dentiality is in a state of flux, becoming
more secure in some societies and less
secure in others. Since it is not possible to
foretell at this time the full implications of
a biomarker ofexposure, effect, or suscepti-
bility, the potential for unforeseen out-
comes (detrimental or beneficial) is very
real. There is a need to provide legal pro-
tection to the participants in the future,
provided the contemporary criteria are ful-
filled. The alternative is to withhold or
delay the use ofbiomarker technology until
greater certainty is achieved.
ProcssandContent
Self-Regulation. ACCOUNTABILITY.
Governments usually relegate control of
science to the subspecialty scientific profes-
sions. It therefore falls on the shoulders of
the scientific organizations to ensure that
guidelines exist against which members of
the subspeciality groups ofscientists can be
held accountable (250). Ethics guidelines,
standards ofpractice, and the development
ofgood laboratory practices are designed to
help maintain objectivity and scrupulous
honesty, so necessary for the advancement
ofknowledge. Adherence to good practices
ofrecord-keeping facilitates the auditing of
laboratories and thereby minimizes the
chances of misconduct in terms of data
handling (i.e., falsification, fabrication, and
plagiarism) (254).
CAPTIVE POPULATIONS. It is currently
recognized that captive populations should
not be included in research because the
prior voluntary consent needed for their
participation can have little meaning in
such circumstances. Furthermore, the sci-
entific validity of findings derived from
captive populations may be ofquestionable
generalizability in the context of the
imposed constraints under which such
participants maylive (255,256).
PRIVACY. The privacy offindings from
research on biomarkers ofsusceptibility has
perhaps a higher level ofpersonal concern
than other personal data. Because such
research can have profound ramifications,
not only for the research participant him/
herself, but also for his/her family (i.e., sib-
lings and offspring), special attention must
be given to respecting the participant's
right to privacy. In research settings gener-
ally, as well as in practice, some level of
uncertainty is associated with the findings
from susceptibility studies. The confidence
with which highly sensitive information
can be shared with the person to whom it
directly relates is not always optimal. The
question, therefore, ofwhether to share
this information (together with its uncer-
tain interpretation) must be raised.
Current deliberations around the principle
of autonomy suggest that the informed
consent process should include the option
ofwhether or not the research participant
would want to know his/her results in the
presence ofno clear interpretation.
Furthermore, whether results for which
no treatment can be offered should be pro-
vided to research participants is a topic that
extends to the underlying principles of
screening, where screening should not be
undertaken unless something can be offered
to remediate the condition. In genetic
marker susceptibility studies, genetic coun-
seling can be offered; inheritable conditions
are viewed as "treatable" through recom-
mendations ofthe option ofabstention or,
more extremely, ofsterilization, an option
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that in the presence of uncertainty, could
result in substantial harm to the individual.
SECURITY. The degree to which informa-
tion is not only to be protected (secured) by
researchers, but also the degree to which it is
to be shared with research participants
should be effectively addressed in applica-
tions for ethics review to institutional review
boards, or human subjects/research ethics
committees. Studies ofbiomarkers ofsus-
ceptibility require special attention to these
details because ofthe heightened sensitivity
associated with such findings. Indeed, owing
to the heightened sensitivity associated with
the information gleaned from studies into
biomarkers ofsusceptibility, special care by
scientific reviewers might include the ques-
tion ofwhether or not the hypothesis or
question being proposed by the study war-
rants being addressed. The latter point flows
from the social values that may or may not
permit such questions to be addressed from
the public purse. The question that then fol-
lows is how to handle the private funding
for research ofahighly sensitive nature.
When research is funded, researchers
need sufficient funds to ensure data secu-
rity and to conduct a study ofadequate sta-
tistical power. Pilot studies, while necessary
for the formulation of a major study pro-
posal, need to be undertaken with as much
attention to data security issues as if they
were full-scale studies.
Concern about the public demand for
tests that are not scientifically validated is
especially serious for biomarker studies.
Whereas syphilis testing remains a required
premarital test in many countries, in part
because a treatment is available, this is not
the situation for many markers ofsuscepti-
bility, especially genetic markers. Where
genetic markers are not clearly inter-
pretable, more harm than good could
result from access to such testing; certainly,
in the current state ofdevelopment, few
cures or treatments are possible. Until such
time as society recognizes genetic aberra-
tions as a part ofthe normal range ofbio-
logical diversity, the desire to eliminate
that which can be eliminated within the
constraints ofrespect for life will continue.
RIGHT TO KNOW AND NOT TO KNOW.
Do we have the right to know our personal
genetic characteristics? The peculiar and
highly sensitive nature ofsuch knowledge
indicates that certain limits and precau-
tions may need to be considered in view of
the serious potential consequences ofsuch
disclosures for the individual, for relatives,
and for children. Knowledge ofan individ-
ual's genetic characteristics can, in some
cases and, with some limitations, provide
knowledge about the genetic characteristics
ofhis/her relatives.
We also can consider that we have the
right notto know our own genetic charac-
teristics, the right to a carefree life, and to
remain ignorant about our own lot.
Because genetic screening could lead to
fatalistic or pathological behavior, some
people might prefer to remain ignorant of
this information. Such an attitude would
deserve the same respect as the one that
demands the most exhaustive information
about one's state ofhealth. If, however, off-
spring are planned and, say, a 50% chance
oftransmission ofa serious genetic defect
exists, should the noncarrying spouse and,
for that matter, the carrier, be forced to
knowor be providedwith the information?
SCIENTIFIC INTEGRITY. The importance
ofensuring absolute integrity in scientific
studies involving highly sensitive infor-
mation is apparent. Hence, methods of
laboratory procedures that minimize the
risk ofdata falsification and fabrication are
all the more important. Greater scrutiny
(oversight) ofthese studies is in order.
Conflicting interests must be protected
against. These could arise in biomarker
studies in which premature results are pub-
lished and the public demand for the
"new" test serves the interests ofthe manu-
facturers (and its shareholders or stock-
holders) at a time when the test results may
cause more concern through the inability
to interpret the results.
When population-based studies are
undertaken to determine the prevalence of
any susceptibility factor, unlinked studies
might be preferable by virtue oftheir total
anonymity. In drawing biological speci-
mens for these or other studies, however,
informed consent dictates adherence also
to the principle ofveracity and fidelity in
honoring commitments to, for example,
privacy and to the withholding of, or the
communication of, results.
CONTINUING EDUCATION. Because pro-
fessions are expected to be selfregulating,
the production of this document is one
mechanism bywhich the continuing educa-
tion of researchers engaged in studies of
biomarkers ofsusceptibility, as well as their
students, can be kept abreast ofadvances in
the field. Constructive criticism ofany of
the ethics guides presented herein should be
encouraged, given that societal values and
technology differ and change over time.
The need to engage the public and stake-
holder interest groups in this discussion,
while difficult, cannot be overstressed.
Communication. Communicating and
campaigning with different categories of
scientific bodies, nonscientific bodies, and
other concerned organizations, are as
important as the discovery ofgenetic tests
themselves. Satisfying the concerns ofthose
bodies will facilitate the approval and
application ofthose methods, rendering
them more effective.
The current practice ofgenetic tech-
niques offered by researchers for protection,
selection, or surveillance ofsusceptible per-
sons to chemical environmental exposure
needs to be scientifically sound with honest
information and validated standards.
Then these techniques can be presented for
peer review.
Researchers also should inform and
explain such methods to important groups
such as health authorities, general or family
physicians, occupational health physicians,
trade unions, legislators, and administra-
tors. They should explain the benefits of
the work, as well as the risk assessment
findings and possible risk management
approaches to be considered. Other scien-
tific bodies and researchers can be informed
through scientific journals, periodicals, lec-
tures, conferences, and special symposia
andworkshops.
Information to the general public using
mass media techniques can be handled
through the public press, radio, and tele-
vision applying simplified, understandable,
and uncomplicated language. Risk com-
munication with the general public should
be provided for in lay terms. People who
undergo such tests can be informed or not
informed depending on their wish to know
or not to know. Information to family mem-
bers, children, and siblings depends mainly
on localvalues and on legal requirements.
Stakeholder Involvement. As a key
stakeholder in the development of bio-
marker technology, the scientist is socially
accountable. The whole question ofdeter-
mining biomarkers of exposure, effects,
and susceptibility leads to assessments of
the health of individuals and populations
as well as considerations ofthe use ofbiol-
ogy in social relationships. For example,
ethics, as a guiding narrative for those
making scientific claims, is situated at the
interface between the scientific discourse
on susceptibility and the general, social
discourse on professional ethics. Within
ethics, ethical principles and basic human
rights become visible. While ethical princi-
ples include autonomy, beneficence, non-
maleficence and distributive justice, basic
human rights such as the right to health,
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the right to work, and the right to privacy
emerge concurrently.
As these principles and rights become
established as collective values, it is the
duty of-all stakeholders involved to ensure
that they indeed are upheld. One way to
ensure this is to maintain open lines of
communication among the various groups
ofstakeholders. Here, the process ofimple-
menting the ethical principles ofveracity
and fidelity become clear.
Science is not value neutral in that the
direction ofscientific pursuit is determined
by asynthesis ofthevalue ofknowledge for
its own sake and the value ofknowledge
for social benefit. All stakeholders should
be made aware of the nature and limita-
tions ofthe scientific method: that it func-
tions by observation, hypothesis, and
experiment and requires a tightly con-
trolled methodology for it to provide reli-
able results. By the same token, although
investigating a universe that is governed by
the absolute laws of nature, science can
never provide an absolute result but
phrases its conclusions on the best available
evidence at the time. These conclusions are
likely to change in the future as new
hypotheses and subsequent data about the
laws ofnature are gathered. Science strives
to minimize-but can never eliminate-
uncertainty. For these reasons, the process
ofscience must be transparent to all partic-
ipants, including the research participants
themselves, witnesses, and communicators
of results. Furthermore, in the interests of
reliability, credibility, and durability, the
understandable demands for the premature
release ofdata, drugs, and technologies
must be resisted according to the ethical
principle ofnonmaleficence.
In advocating for a position favorable
to science, medicine, or public health, the
scientist should retain the identity and
adhere to the standards ofscience-objec-
tivity, impartiality, and stating limitations
and uncertainties-because the audience
always will lend the scientist the credibility
of science. To abandon these principles
may endanger the stature of science in
terms of the scientists' obligation to
improve the state ofhumankind. The need
for scientists to convey an attitude of
"healthy scepticism" should support the
role ofscience in the public interest.
CaseStudies
The recognition ofbiomarkers in combina-
tion with the rapid development of new
methods in molecular genetics andanalytical
biochemistry havefacilitated the screeningof
individuals for genetic variations ofdirect
relevance for susceptibility to environmen-
tal factors and diseases. These biomarkers
can be analyzed at different levels, indicat-
ing differences in metabolic conversion of
chemicals, differences in uptake and expo-
sure to DNA-binding chemicals, differ-
ences in genetic effects ofchemicals, and
hereditary differences predisposing to dis-
eases. Several case studies are used to exem-
plify these applications. The concluding
section ofeach case study attempts to draw
out relevant ethical tensions or to highlight
particular ethical principles.
Metabolic Variation. Chemicals to
which people are exposed are primarily
detoxified in the liver by essentially two
systems-one that converts chemicals with
low water solubility to soluble metabolites
(cytochrome P450) and one thatcauses con-
jugation to glutathione (glutathione S-trans-
ferases) and to some othercompounds.
Of relevance in the present context is
the fact that both enzyme systems embrace
genetic variants that affect the efficiency
with which potentially harmful chemicals
are metabolized or conjugated to innocent
or less toxic chemical components.
Individuals lacking or carrying variants of
some ofthe genes for metabolism and con-
jugation exhibit an increased susceptibility
to carcinogenic chemicals in the environ-
ment. This increased susceptibility has
been indicated by the observation of an
increase in the binding ofthe chemicals to
DNA, the increase of cytological effects
such as chromosome breakage, sister chro-
matid exchange, formation ofmicronudei,
and an increase ofpoint mutations (46).
The recognition ofindividuals who are
subjected to a potentially increased risk of
cancer from this exposure poses the ethical
dilemma common to much ofthe present
development of biomarker applications:
how to prevent susceptible individuals
(particularly those occupationally exposed)
from being exposed to these chemicals. In
this context, a tension appears between the
human right to work and the ethical prin-
ciple ofnonmaleficence. To resolve this
tension, scientists should consider more
fully the principle ofsolidarity. In addi-
tion, scientists should work in conjunction
with public health officials who, at the
same time, tend to uphold the principle of
socialjustice.
Mutations Predisposing to Human
Diseases. In the last few years, the
characterization ofgenetic factors involved
in human disease has undergone a dramatic
development. A great number ofgenes now
have been localized and the DNA to a
great extent has been sequenced. The
human genome project, HUGO, which
implies the sequencing ofthe total human
genome can be expected to provide much
new material in this respect. A shortcut in
this procedure has been performed with
"expressed sequence tag" through which
mRNA is used instead ofDNA to identify
human coding genes. DNA ofthe coding
genes is collected by enzymatic conversion
ofmRNA to cDNA. With this technique,
the work can be focused on the 3 to 4% of
the human DNA giving rise to genes. To
date, about 50,000 of the 70,000 to
100,000 genes have been identified. This
material already has played a crucial role
for the characterization ofthe mismatched
repair genes particularly involved in human
colorectal cancer (below). This will put the
person concerned, the physician, and the
administrator into a dilemma on how to
handle such information and how to pro-
tect the person. Ifthe ethical rules will be
applied and the test with its pros and cons
explained to the person beforehand, this
should provide reasonable resolution to
potential dilemmas.
Repeated DNA Sequences. Among
genetic variants in the human population
giving rise to diseases, repeated DNA
sequences have attracted a great deal of
attention in recent years. Repeated DNA
sequences of relevance in this context of
biomarkers concern amplification ofcod-
ing genes as well as short repeated
sequences, minisatellite and microsatellite
DNA (134).
Amplification resulting in overexpres-
sion ofcoding genes is a regular phenome-
non under certain circumstances (257).
The gene for metallothionein protects
against heavy metals, and exposure to
heavy metals can cause an induction and
an amplification ofthis gene (258). The
subsequent increase of the protein there-
fore can be a biomarker for exposure to
heavy metals like cadmium and mercury.
Of pathological importance is the
occurrence ofamplification particularly of
nuclear oncogenes such as c-myc. Such
amplification has been suggested as a bio-
marker of some prognosis value in breast
cancer patients (259).
An essential part of the noncoding
DNA is built up of short, repeated
sequences and some ofthat DNA exhibits
a pronounced instability, particularly
involving length alterations. The function
of this DNA has been and remains
obscure, but in recent years.several serious
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human diseases have been associated with
short, repeated DNA sequences, minisatel-
lites (10-100 bp) and microsatellites
(2-4 bp).
One case of pathological connection
with minisatellites concerns a minisatellite
associated with the oncogene ras. Some
rare variants ofthis minisatellite are associ-
ated with multiple forms ofhuman can-
cers. It is thus possible to identify carriers
ofthese rare minisatellite alleles that result
in asignificandy increased risk for cancer.
Microsatellites are particularly impor-
tant as biomarkers and the cause ofsome
serious human neurological disorders. The
microsatellites are linked to the actual
genes involved in the disorders and an
extension ofthe repeated DNA sequences
above a certain number causes the disease.
An important aspect of this process is the
fact that the amplification tends to increase
from one generation to the next, making
the disease gradually more serious with
earlier onset-"genetic anticipation."
These microsatellite-linked diseases
involve, for instance, fragile X, which is
one ofthe most prevalent mental retarda-
tion conditions, and the well-known
Huntington's disease. Huntington's disease
causes a neurological disintegration with
onset usually in the age range of 40 to
60 years.
The genetic predisposition for these
diseases is passed on to 50% of the off-
spring and appropriate testing will predict
disease in the offspring. Only occasionally
has it happened that the number of
repeated DNA sequences has diminished
from one generation to the next. The fact
that Huntington's disease (as well as other
neurological diseases) is incurable poses
many ethical problems at the individual
and family level, such as testing the off-
spring and other family members; offering
prenatal diagnosis; or deciding whether or
not abortion should be performed.
Traditional debates in this area expose
major tensions between the ethical princi-
ples of autonomy, expressed by those
upholding the right to choose, and non-
maleficence, implicit in those opposing
abortion. While this tension has not yet
been adequately resolved, scientists as well
as public health professionals would benefit
from considering how developments in
biomarker technology may have the poten-
tial to modify this traditional tension. Ifall
stakeholders involved would agree collec-
tively about what is meant by "human life"
and when it starts, this awareness would
shift the traditional debate into a different
ethical arena. Here, deontology guides the
scientist to stimulate the public's awareness
ofautonomy.
Repair Mutations. It has been known
for over 25 years that a deficiency ofDNA
repair can cause cancer. The classical case
is the recessive autosomal mutation
Xeroderma pigmentosum, which causes a
serious skin disease. Patients with the disease
lack the ability to repair the DNA lesions
caused by ultraviolet light irradiation and
theyinvariably develop skin cancer.
In recent years, several genes involved in
the repair ofmispaired nucleotides, mis-
matched repair, have been characterized
and localized (260). Mutations in these
genes are particularly linked to an elevated
risk ofcolon cancer. The mutations occur
as heterozygotes and the tumors are
induced as the result ofthe loss ofthe wild-
type allele. It has been estimated that this
mutation is carried by 1 in 200 people, and
it thus constitutes one ofthe most prevalent
human disorder mutations. Screening for
this mutation is likely to be recommended,
at least in families that exhibit ahigh rate of
this specific colon cancer-type linked to
deficiency of mismatched repair. Such
screening will fulfill the purpose ofavoiding
malignant growth of tumors by regularly
checking the colon. In addition, it is evi-
dent that exposure to mutagenic and car-
cinogenic agents can be expected to increase
the risk of cancer to a greater extent in
mutant carriers, with possible implications
foroccupational and lifestyle choices.
The fact that susceptibility studies of
colon cancer implicate family members
poses the tension already discussed in the
preceding section "Right to Know and Not
to Know." Nevertheless, varying attitudes
about genetic information-and the
genetic information itself-should be seen
as equally important by both the public
health professional and the scientist.
Reliability of Laboratories and
Methods. Many ofthe analyses ofgenetic
variants and genetic disorders at the molec-
ular level require sophisticated laboratory
techniques and professional knowledge to
properly interpret the data. It is ofpara-
mount importance that laboratories
involved in such analyses are subjected to
quality control to avoid mistakes. For
instance, it is critical that analyses ofmini-
and microsatellite patterns in forensic med-
icine to identify criminals is performed
without any error-the consequences
could otherwise be disastrous. It also has
been pointed out that, although the chance
of two unrelated persons having a similar
genetic pattern is very remote, relationship
has to be excluded in the analysis (261).
On the other hand, correctly performed,
these techniques for characterizing individ-
uals genetically constitute invaluable tools
in forensic medicine, paternity determina-
tion, and epidemiological and population
analysis. The proliferation of these tech-
niques and tools, and their use with indi-
viduals and populations, demand that the
collective scientific value ofquality assur-
ance be maintained. In ethical terms,
the principle ofscientific honesty is most
relevant in laboratory settings.
Impact ofGenetic Monitoring or
Screening on Society. We are doubtless
only in the beginning stages ofthe evolu-
tion ofthe genetic characterization ofindi-
viduals, but already we can foresee many
practical and ethical problems for society.
Solutions must be developed with the ethi-
cal and moral implications defined explic-
itly. When social costs are involved, the
right ofautonomy over such personally sig-
nificant data should be balanced against
the interests of society according to, for
example, principles derived from utilitar-
ian, libertarian, or egalitarian theories
ofethics.
Among the pressing problems is the
question ofwho will have access to the
genetic information of individuals. The
initial governing principle here would seem
to be autonomy. The principle of auton-
omy requires respect for the individual's
right to privacy. However, a tension
emerges when the individual's own actions
can have a negative impact on the group.
The tension is between the individual's
right to privacy and the group's (or the
community's) right to know.
For example, the fact that people can
obtain information about mutations that
are likely to shorten their life expectancy
may become important in securing life
insurance. Attempts to prevent genetic
data from reaching insurance companies
are not likely to be successful in that insur-
ance companies can require the right of
access to medical records as a condition to
considering insurability.
If egalitarian theories are to be fol-
lowed, the cost ofthis insurance riskwould
be shared without penalty across the pool
ofinsured people. Ifeither utilitarian or
libertarian theories are adopted, susceptible
persons might be excluded from the pool
ofinsured, or theymight be charged higher
premiums. It could be foreseen that persons
who know that they carry a life-shortening
genetic condition might purchase large
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amounts oflife insurance and that, in turn,
could cause an economic deterioration of
the insurance system. Prior consideration
of these possibilities might help society to
focus on the risks associated with the
adoption oftechnological advances.
Genetic Screening of Workers. The
recognition that certain genetic polymor-
phisms could be identified in humans (e.g.,
hemoglobin S, G-6-PD deficiency, xl-
antitrypsin deficiency) and could be related
to differential susceptibility, led Stokinger
(262) to advocate their application in
screening for so-called "hypersusceptible
workers." Omenn (223) cautioned against
the blanket application ofsuch techniques
as inadequately predictive of risk, and sev-
eral critics have noted the importance of
controlling workplace exposures instead of
removing susceptible workers from the
workplace (263). Although unusually sus-
ceptible individuals would benefit from not
being exposed to the agents that are likely
to make them sick, this intent should not
be used as an excuse to avoid reducing
exposures in the workplace; nor can it be
invoked to avoid taking differential suscep-
tibility into account in risk assessment
(264). Moreover, none of the genetic
screening programs thus far proposed are
sufficiently predictive of risk. Hence, any
exclusion by virtue of membership in a
genotypic class would be discriminatory, at
least under United States law.
The elimination ofwomen of child-
bearing age from certain occupations is
now deemed illegal in the United States
and represents an example of what is
essentially genetic screening; namely, the
elimination of persons with a particular
genotype (XX) without regard to their
actual susceptibility status.
Ecological Ethics. The emission of
harmful chemicals into the environment
also should be considered from an ecotoxi-
cological point of view. Particularly, the
contamination of the environment with
persistent chemicals like some chlorinated
hydrocarbons and heavy metals can have
serious effects on the ecosystem through
bioaccumulation along the food chain.
Organisms at the top ofthe food chain run
the risk of acute intoxication, reproductive
inability, and behavioral disturbances.
These effects on the ecosystem are relevant
for the preservation ofbiological diversity
in accordance with the convention ofbio-
diversity accepted by the United Nations
conference on environment and develop-
ment in Rio de Janeiro, 1992. But besides
our moral obligation to take into account
effects on the ecosystem and biodiversity,
the monitoring of ecotoxicological effects
often can have relevance to human health.
The human species is also at the top of
the food chain and is often exposed in the
same way as other species at this trophic
level. The recent focus on chlorinated com-
pounds like PCBs, DDT, and tetrachloro-
dioxin, because of hormonal effects, may
serve as a further warning signal for human
beings. The deontologic duty ofhumans to
serve as stewards of the environment for
their own self interest and that of future
generations is highlighted in this context.
This duty enhances the right to life of
other species.
Ethical Components ofBiomarker
Project Proposals
Parties responsible for biomarker studies
need to ensure that the broad range ofper-
sons involved in the planning, implemen-
tation, and outcome of projects (the
stakeholders) are provided the protection
ofexplicit ethical principles under which a
project will be conducted. Persons involved
include the study participants, the benefi-
ciaries (including both participants and
nonparticipants), the community (special
and general), those gathering the data
(researchers and surveyors), employers,
trade unions, regulators, sponsors, and
other potential recipients ofthe results.
The ethical issues to be addressed
include the following:
* autonomy ofthe participant in partici-
pating, including fully informed consent
* beneficence of the project for the
persons and institutions affected
* absence of maleficence toward the
participants and institutions affected
* assurance of justice (equity among
participants and nonparticipants)
* test validity as a function of the target
population, including consideration of
the degree of risk, exposure, and other
factors
* explicit provisions to ensure equal
access to participation across race, social
class, and gender as appropriate to the
attribute under study
* nonabridgement of deontologic (duty-
based) obligations ofthe participants
* scientific integrity and soundness
* confidentiality and security of data,
including anonymity and nonlinkage to
the individual
* referral for treatment and counseling for
a significant incidental medical finding
h assurance that a recognized public
health or legal risk will be reported
* formulated response to anticipated
questions about biomarker findings
* identification and allocation of legal
liability
* formats and pathways for communicat-
ing study results, including publication,
media and employer
* sponsorship, conflict of interest; clear
understanding ofdeliverables warranted
for funding received
* action to be taken in the event of an
untoward finding, including employ-
ment status
* future mutual obligations of partici-
pants in the event ofnew developments.
Condusions
A number of conclusions can be drawn,
particularly the following:
a) Because the issues contained herein
are from the scientist's perspective, the
attention ofother stakeholders is called for.
b) The positive aspects of biomarker
technologies must be emphasized without
failing to recognize the potential for their
misuse.
c) There is a need to continue research
to produce better evidence concerning sus-
ceptibility markers while simultaneously
protecting against any misuse ofpremature
or tentative evidence.
d) The active participation ofthe pub-
lic is to be sought in a partnership capacity
to ensure the advancement of knowledge
concerning biomarkers for identifying
susceptible people and populations.
e) It must be recognized that science is
imperfect. Uncertainty is inherent to the
scientific method and varies as a function
ofthe evolution ofscientific knowledge.
f) The imperfections ofscience require
humility on the part ofscientists. Science is
but one part of a number of inputs for
decision making.
g) For every decision that is made, the
tension between risk and benefit should be
considered.
h) Good science should be tied to good
ethics and vice versa.
i) An unintended consequence of
biomarker technology is that individuals
and populations could be discriminated
against.
j) Until the scientists involved with
developing a new susceptibility biomarker
technology have declared it adequately
reliable and accurate and after full peer
review, the public should be protected
from commercial interests that wish to pre-
maturely release the technology into the
market place.
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Recommendations
Participants in preparing this report make
the following recommendations:
a) Because a multidisciplinary group
assessed the ethical dimensions of each
respective subspecialty discipline, this
report ought to carry some authoritative
weight in the context ofprofessional ethics.
b) Professionals and their students need
to engage in an ongoing dialogue concern-
ing applied ethics.
c) Legislation needs to be developed to
protect all interests against liability that
could be judged in hindsight arising from
changes in ethical standards and scientific
knowledge over time (i.e., against retro-
spective tort action in soundly conducted
studies because of intervening changes in
social and ethical standards or advances in
scientific knowledge).
d) There is a need for guidelines
concerning biomarker susceptibility studies
for use by researchers andpractitioners alike,
which also would be ofuse in the training of
students. Other agencies that have engaged
in related deliberations (such as those con-
cerning the Human Genome Project and
the U.S. Office ofTechnology Assessment),
should be sought out for collaboration since
they have developed guidelines in the area
andrelated areas.
e) Every research proposal in the
area of biomarker susceptibility should
address the ethical dimensions ofthe pro-
posed study. In addition, strategies for
communication, from peer review through
individuals and the public, should be doc-
umented. Studies in biomarker susceptibil-
ity should be audited for adherence to
proposed intentions.
f) Scientists must be vigilant in
developing ethics guidelines in that they
should ensure equity across all segments of
society. All guidelines should be sensitive
to cultural differences.
g) Because of the extremely sensitive
(i.e., intimately personal) nature of the
information gleaned from biomarker
susceptibility studies, extraordinary pre-
cautions relating to the privacy of the
information are to be exercised.
h) Specific guidelines on how industry
and insurance companies might deal with
individuals discovered to have a suscepti-
bility are beyond the scope of this text.
However, attention is drawn to this since
guidelines in these specific areas may be
aided by the discussion contained in
this section.
Appendix
Analysis and Quality
Assurance
Laboratory results are only useful ifthey are
accurate and precise, and are reported in a
responsible manner. Accuracy refers to the
ability ofthe analyst to determine the exact
quantity present in asample. Precision refers
to the ability to provide a consistent result
(which may not necessarily be accurate, if
for example, there is a failure in calibration).
QA represents the sum total ofactivities that
are required to produce reliable results (good
precision and accuracy). In terms oflabora-
tory analysis it includes setting data quality
objectives on the one hand and evaluating
quality control measures on the other.
Stating a data quality objective consistent
with the goals ofthe screening program or
study is a necessary first step. Lack of
resources or power sufficient to meet these
objectives is grounds for not doing the
study. Excessive power increases the cost.
Standard QC procedures have been
well documented. Most published method-
ologies include QC procedures which must
be individualized for each laboratory and
each analytic instrument and procedure.
Each laboratory must have a written
QA/QC statement and protocol. These
should be very detailed, including, for
example, assurance that the deionized
water is free ofanalytes in question, at least
within the limits of detection required.
Similarly, the purity of the solvents and
reagents and the source of all standards
should be specified.
Calibration procedures should use
blanks and fresh standards within the range
ofanticipated concentrations. (One can
only assume that a method yields linear
results within the range of the calibration
curve). The method detection limit should
be specified for each analyte in each matrix
(blood, urine, hair, etc). Field and method
blanks should assure that there is no conta-
mination at any point in the collection and
analysis ofsamples. Spiked samples should
assure that the technique can recover the
analyte from the matrix. This allows one to
document the percent recovery ofthe spike
from the sample. Unless otherwise speci-
fied, it is customary to require that each
analytic run produce a recovery between 85
and 115% of the actual spike. For some
analytes it is difficult to achieve this level of
accuracy on certain instruments, while for
others tighter limits are routine. Ifrecovery
lies outside a certain range ofvalues, then
the entire run is rejected, and the stored
samples are redigested and reanalyzed.
Alternatively, some procedures allow the
correction of the analytic results by the
recovery percent. Thus if the recovery is
only 80% ofthe spike, the results can be
multiplied by 1.25 to correct for the defi-
ciency. This approach is much less desir-
able and should be avoided, unless there is
no further material available for analysis or
unless the method repeatedly results in a
similar recovery.
Each laboratory should participate
regularly in a proficiency testing program
involving the blind analysis of unknown
samples provided by a reference laboratory.
The results ofsuch testing should be main-
tained with the QA/QC documents and
should be available for inspection.
Challengesfor
Susceptibility Monitoring
in Developing Nations
In many cases through international coop-
eration, developing nations are able to
mount sophisticated screening programs
for environmental as well as infectious
agents. For example, the Mexican govern-
ment, with the support ofseveral interna-
tional agencies such as United Nations
Environmental Program, has been able to
evaluate the exposure and possible effects
of chemicals on human health for both
acute and long-term exposures (Table Al).
However, such programs can only touch
the surface ofthe environmental pollution
problems present throughout the world.
Moreover, at the same time that indus-
trialization is increasing in areas with
minimal environmental regulation and
enforcement, the developed nations are
cutting back on funding for international
cooperative programs.
Guidelinesforthe
Implementation
of Biomarker Studies
In any program the number ofguidelines
should be considered in implementing any
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Table Al. Assessment ofexposure using various approaches: examples from Mexico.
Exposures Monitoring level Test
Acute
Chlorine gas tank leak, Mexico City Clinical Spirometry
Smelter emissions, El Paso, Texas Blood level Lead, cadmium, zinc
Metal exposure (10-yearfollowup) conduction Neurological Peroneal nerve
Blood level Lead, cadmium, zinc
Cows raised on farmland with high natural Food chain As in milk
arsenic content exposure
Chronic
Studies of air pollution prevalence,a Mexico City Questionnaire symptom
Studies ofairpollution, Mexico City Clinical Vital capacity in children
International 10-city study of lead exposure Blood lead level
in schoolteachers
Study ofschoolteacher exposure, Mexico City Environmental media Air, food, water, soil,
cooking pottery
Organochlorine pesticide exposures in Breast milk DDTand other
representative sample ofwomen, Mexico City organochlorines
Carbon monoxide levels in workers exposed Blood Carboxyhemoglobin
on streets, Mexico City
"Dailyfrequency ofrespiratory symptoms in elderly orchronically ill people.
screening program for biomarkers. These
guidelines should include the following:
Overali QualityPlanning
a) The economic resources available for
the program must be identified.
b) The benefits of the program must be
justified to assure adequate funding.
c) The intervention must be specified and
funds identified in advance, ifpossible.
d) Where resources are not available for
the "best" methodology, the use of
alternative tests must be evaluated.
QualityAssurance
a) The screening protocol should include
a statement ofthe data objectives and
the required detection limits, the antici-
pated range ofvalues, and the accept-
able limits for precision and accuracy.
b) High quality laboratories should be
identified.
c) All participating laboratories should
have a written QA/QC document
which should include documentation
of participation in some Laboratory
Proficiency program.
d) The protocol should allow for an inter-
nal QC program including blind repli-
cates and confirmation of some
percentage ofthe samples by an exter-
nal reference laboratory.
e) Data quality evaluation should be com-
pleted prior to data analysis.
Standards for Collection ofSamples
a) The population to be studied should be
clearly identified and the people to be
screened should be representative ofthe
population ofinterest (minimize con-
founders).
b) All personnel should be selected care-
fully and should be conscientious and
responsible.
c) All personnel (registrars, interviewers,
phlebotomists, etc.) should be carefully
trained and periodically evaluated.
d) Field sampling conditions should be
made as ideal as possible. Use extreme
precautions to avoid contaminating
samples ofblood, urine, etc. at the time
ofcollection.
e) Care must be taken in the transporta-
tion of samples from the field to the
central laboratory, particularly ifsam-
ples require freezing or refrigeration.
f) All samples must be carefully and accu-
rately labeled and a chain-of-custody
form may be desirable for certain study
situations.
LaboratoryStandards and Practices
a) High-quality laboratory facilities are
essential.
b) Where possible, a laboratory that is
already functioning and ofproven qual-
ity should be used.
c) Whether old or new, laboratories
should be designed to eliminate both
external and internal sources ofconta-
mination. This requires high standards
ofdesign and maintenance.
d) Laboratory equipment should be appro-
priate for the analyses beingperformed.
e) The appropriate preservation of sam-
ples is important, so facilities should
have reliable refrigeration, preferably
with a backup source of emergency
electricity (gasoline generator).
f) All laboratory personnel should be
trained; usually this will require train-
ing at an analytic center in a major city
or outside the country. Training should
embody the general principles oflabo-
ratory QA/QC and should also be rele-
vant to the equipment available for use
in the laboratory.
g) All results should be carefully checked
for internal consistency. Deviant results
should be repeated.
h) Laboratory supervision should be strict
andconsistent to assurehighqualitydata.
Results
a) There should be adequate computing
facilities and trained personnel for
analysis ofdata.
b) All individual results should be treated
as confidential and individuals should
be informed of their own results with
adequate information as medically
appropriate.
c) Thesuppression ofresultsforeconomic or
political reasons is strongly discouraged.
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